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Over the last few years there has been an explosion of
the knowledge of normal B-cell physiology particularly in
the area of control of B-cell activation, proliferation
and differentiation. This has been augmented by the
availability of a large number of monoclonal antibodies
which recognise a wide range of molecules expressed at
the cell surface by B-cells at different stages of acti¬
vation and differentiation. Non-Hodgkin's lymphomas are
believed to result from the uncontrolled proliferation
and accumulation of B-cells arrested at different stages
of differentiation. Currently used classifications of
non-Hodgkin's lymphoma are based on this idea and morpho¬
logically eguivalent normal and neoplastic cells may be
identified. Monoclonal antibodies which detect surface
antigens on B-cells may be used by immunohistological
techniques to accurately phenotype both neoplastic and
equivalent normal cells. Detailed phenotyping using a
panel of antibodies against surface antigens may allow
more accurate classification of non-Hodgkin's lymphoma
and comparison with presumed normal equivalents. As many
of the surface markers expressed by B-cells have been
shown recently to be important in cell activation it is
possible that their expression may be important in uncon¬
trolled growth and have prognostic significance.
This investigation was undertaken in an attempt to evalu¬
ate the usefulness of such detailed phenotyping in the
pathological diagnosis and classification of non-Hodg-
kin's lymphoma and to evaluate the prognostic signifi¬
cance of antigens whose expression was associated with
cell proliferation and differentiation.
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The results show that there is extensive immunophenotypic
heterogeneity in B-cell lymphomas. Differences in antigen
expression are seen between cells of individual cases and
between morphologically similar groups of tumours but
certain patterns of antigen expression were present. CD
antigens 5, 10, and 23 were expressed significantly more
often by low grade lymphomas, CD5 expression being almost
exclusive to lymphocytic and centrocytic groups. CD38,
4F2 antigen and CD71 were more often expressed by high
grade lymphoma.
The phenotypic heterogeneity exposed by detailed pheno-
typing creates difficulty for comparison with normal
equivalents and mitigates against its use for diagnostic
purposes. Nevertheless a limited panel of antibodies has
been identified which would be suitable and useful for
routine use. Although many of the antigens studied were
known to be involved with the control of normal B-cell
proliferation the expression of only two were shown to be
of prognostic value. There was a significant correlation
with survival and expression of 4F2 antigen and CD71
(transferrin receptor) . 4F2 antigen and CD71 may identify
a poor prognostic group of cases in low grade lymphoma
but phenotyping B-cell non-Hodgkin's lymphoma for many of
the antigens expressed at various stages of B-cell dif¬
ferentiation and activation does not provide clinically




Over the last few years there has been an increase in
the understanding of normal B-cell physiology. This has
been assisted by the production of monoclonal anti¬
bodies (MCA) against novel antigens expressed at dif¬
ferent stages of B-cell activation and maturation
(Bernard et al 1984, Reinherz et al 1986, McMichael et
al 1987). The morphology and distribution of distinct
B-cell subsets in lymphoid tissue has been elucidated
and correlated with antigen expression (Stein et al
1982, Campana et al 1985, Nadler 1986, Ling et al
1987) . In-vitro studies of activation and differentia¬
tion of B-cells have shown sequential changes of anti¬
gen expression by these cells as they transit the cell
cycle or undergo terminal differentiation (Boyd et al
1985a, 1986, Smeland et al 1985, Walker and Gordon
1987). It is becoming clear that such antigens may be
important receptors for soluble mediators involved in
the control of B-cell growth and differentiation (Clark
and Einfield 1986, Frade et al 1985b, Muraguchi et al
1985b, Clark and Ledbetter 1989). As many of these
antigens appear to be involved with cell proliferation
it is possible that their expression by neoplastic
cells may be related to uncontrolled proliferation and
clinical prognosis.
Non-Hodgkin's lymphomas (NHL) are a group of neoplasms
which are believed to arise as a result of uncon¬
trolled proliferation and accumulation of lymphoid
cells arrested at a set maturation stage (Lukes and
Collins 1974). They show cytomorphological and some
phenotypic similarities to cells in normal lymphoid
tissues. Presently used classifications of NHL such as
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the Kiel classification (Lennert 1978, Stansfeld et al
1988) are based on these features. Detailed phenotyping
with a panel of activation and differentiation antigens
should allow more accurate comparison between normal
and neoplastic B-cells and may lead to more accurate
classification of lymphoma.
This study was undertaken to investigate these possi¬
bilities.
In the remainder of Chapter 1 I shall review what is
known of normal B-cell distribution and maturation in
human lymphoid tissue and the factors controlling B-
cell activation and differentiation including the
function and distribution of the antigens studied in
this work. I shall also discuss briefly the classifica¬
tion of NHL and factors which may have clinical prog¬
nostic relevance. In Chapter 2 I will describe the
materials and methods used in this study. Chapter 3
includes the results and discussion of antigen expres¬
sion in reactive lymphoid tissue whereas in Chapter 4
the results of analyses of antigen expression by NHL
will be shown and their significance discussed. Finally
in Chapter 5 the relationship of antigen expression to
clinical parameters including survival will be present¬
ed and discussed.
1.1 ORGANISATION OF B CELLS IN PERIPHERAL LYMPHOID
TISSUE
B lymphocytes are present circulating in blood, in
lymphoid tissue of spleen, lymph nodes and mucosa
associated lymphoid tissue. Smaller numbers of mature
lymphocytes are present in bone marrow.
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1.1.1 Lymph Nodes
The architecture of lymph nodes is generally separated
into cortex, paracortex, medulla and sinuses (Stein et
al 1982, Van der Valk and Meijer 1988). The cortex is
the predominant B-cell rich area with both primary and
secondary lymphoid follicles. Primary follicles are
collections of mature small lymphocytes. Secondary
follicles comprise a mantle of small lymphocytes which
surrounds a germinal centre consisting of a population
of proliferating and maturing B-cells, centroblasts and
centrocytes, as well as a number of accessory cells
including dendritic cells tingible body macrophages
and T-cells (Stein et al 1982). Small numbers of B-
cells may also be identified in the paracortex a
predominantly T-cell rich area. The medullary cords
contain large numbers of plasma cells, small lympho¬
cytes, lymphoplasmacytoid cells and smaller numbers of
immunoblasts. A population of B lymphocytes, monocy-
toid B-cells, are present in sinuses in certain condi¬
tions such as toxoplasmosis and AIDS (Sheibani et al
1985). A marginal zone of B-cells (vide infra) is only
seen infrequently in lymph nodes (Van der Valk and
Meijer 1988).
1.1.2 Spleen
The B lymphocyte population in the spleen is predomi¬
nantly in the Malpighian follicles that constitute the
white pulp. B lymphocytes are collected as primary and
secondary follicles as in the lymph node but in addi¬
tion a further anatomically distinct group of marginal
zone lymphocytes can be identified around the mantle of
the B-cell follicle, at the edge of the white pulp (Van
Krieken and te Velde 1988).
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1.1.3 Mucosa Associated Lymphoid Tissue (MALT)
Diffuse aggregates of non-encapsulated lymphoid tissue
are present in the lamina propria and submucosa of a
number of organs including the respiratory and gastro¬
intestinal tracts and have been termed MALT. Lymphoid
cells recirculate and home specifically to these mucos¬
al tissues (Parrot 1976). MALT has both B-cell and T-
cell areas (Spencer et al 1985, 1986, Isaacson and
Spencer 1987). The B-cell compartment includes folli¬
cles and, in a zone between follicles and the overlying
epithelium, small lymphoid cells with irregular nuclei
resembling centrocytes and some plasma cells (Spencer
et al 1985, 1986). These small lymphoid cells which
have been termed centrocyte-like cells resemble spleen
marginal zone cells phenotypically (Spencer et al 1985,
1986).
1.2 B CELL DEVELOPMENT AND MATURATION
The B lymphocyte lineage is characterised by the syn¬
thesis of Immunoglobulin (Ig). The major product of
adult marrow lymphopoiesis is a virgin, small B lympho¬
cyte. These cells migrate to peripheral lymphoid tissue
where they may encounter antigen and differentiate into
immunoglobulin secreting cells - plasma cells. Normal
B-cell development can conveniently be separated into
three stages :- an antigen-independant maturation in
bone marrow, antigen-dependant clonal expansion and
maturation in peripheral lymphoid tissue, where a
number of distinct subsets of B-cells probably exist,
and terminal differentiation to immunoglobulin secret¬
ing plasma cells.
Most understanding of in-vivo B lymphocyte maturation
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has come from analysis of the cellular component of
primary follicles as they appear in the fetus and the
features of germinal centres developing in secondary
lymphoid follicles. Additional information has been
obtained by extrapolation from comparisons between
lymphomas, leukaemias, cell lines and postulated normal
equivalent cells. In-vitro work has added information
on which factors may be necessary for control of B-cell
activation, growth and differentiation and which alter¬
ations occur at the cell surface as a result of changes
in activated state and differentiation. Figure 1.1
(page 12) summarises the current thoughts on expression
of surface antigens at different stages of B-cell
development.
1.2.1 Antigen-Independent Bone Marrow Maturation
Purification of lymphoid progenitor cells from fetal
bone marrow shows a population of immature lymphoid
cells expressing HLA DR and TdT (Hokland et al 1983).
Ig heavy chain gene rearrangement occurs in these cells
(Cooper 1987). Stimulation of HLA DR, TdT positive
cells with PMA-conditioned medium results in sequential
acquisition of CD19, CD22, CD10, CD20 and cytoplasmic
Ig without surface Ig (Hokland et al 1985, Campana et
al 1985, Ling et al 1987). Other markers which have
been identified on pre-B-cells (characterised by the
expression of cytoplasmic mu heavy chain (Raff et al
1976)) include CD9, CD22, CD38 and CD45 (Zola et al
1983, Tedder et al 1984, Campana et al 1985, Kincade
1987). These cells do not express light chains or
surface Ig. They appear in human fetal liver at about 8
weeks (Gathings et al 1977) and are present in the
bone marrow from around the fifteenth to sixteenth week
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of gestation (Bodger et al 1983, Bofill et al 1985,
Hokland et al 1985). Surface Ig positive B-cells are
seen about a week later. Transition to a surface Ig
positive cell is closely associated with light chain
Ig gene rearrangement and with light chain synthesis
(Siden et al 1981). These surface Ig positive cells do
not express CD10 or TdT (Hokland et al 1985). The
transition of a pre-B-cell to a surface Ig positive B-
cell also involves loss of CD38 and acquisition of CD21
(Tedder et al 1984).
1.2.2. Antigen-Dependent Peripheral B-cell Maturation
Mature peripheral B-cells are heterogeneous in respect
of tissue distribution and phenotypic expression and it
is probable that several subsets exist. B-cells are
produced in large numbers from the bone marrow - in the
adult mouse the number produced daily represents ap¬
proximately 20% of the total peripheral lymphoid tissue
(Opstelten and Osmond 1985) - but most of these die.
A small number are selected for long term survival
(MacLennen and Gray 1986). These may either be long
lived virgin cells or newly produced memory B-cell
clones resulting from activation by antigen in periph¬
eral lymphoid tissue. This phase of activation is
believed to occur in extrafollicular areas predominant¬
ly in lymphatic sinusoids and at the cortico-medullary
junction (Lortan et al 1987) and results in the produc¬
tion of a population of circulating memory B-cells.
Germinal centres may also give rise to memory cells
(vide infra).
Peripheral blood B lymphocytes are believed to be
predominantly memory cells which are recirculating from
thoracic duct via blood, through high endothelial
venules to migrate and repopulate primary and secondary
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follicles (Niewenhaus and Ford 1976).
Different populations of B-cells are recognised in the
primary follicles, mantle zone and germinal centres of
secondary follicles of lymph nodes (Stein et al 1982).
Populations with phenotypic and morphologic differences
are seen in the marginal zone of the spleen and lymph
nodes and adjacent to Peyers patches in the gut (Gray
et al 1982, Spencer et al 1985,1986, Van-der Valk and
Meijer 1988). In fetal primary follicles at least two
subsets of B-cells (CD5 positive and negative) can be
identified (Bofill et al 1985).
1.2.2.1 Primary Follicles and the Germinal Centre
Reaction
Primary follicle B-cells in the fetus and adult show
different phenotypic profiles. In the adult the pri¬
mary follicle comprises a collection of mature small
lymphocytes which express surface IgM and IgD (Stein et
al 1982) whereas in the fetus two populations can be
identified (Bofill et al 1985). The majority (60%)
population has a phenotype similar to that of adult
primary follicles, surface IgM and IgD positive, where¬
as the smaller population in addition express CD5.
The phenotype of cells in primary follicles and mantle
zone cells around germinal centres is similar to mature
B cells which emerge from the bone marrow (i IgM, IgD,
CD19, CD20, CD21, CD22, CD24 positive) (Campana et al
1985). This supports the idea that these are either
long lived virgin cells, newly produced memory cells or
both.
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The development of lymph follicles has been studied
during embryogenesis, in neonates and in adults. Only
primary follicles are present in embryos. Germinal
centres arise only after antigenic stimulation follow¬
ing birth. Primary follicles comprise tight clusters
of small lymphocytes. Secondary follicles consist of a
germinal centre and a cuff of mature small lymphocytes
the mantle zone. Following antigen stimulation
secondary follicles develop from primary follicles and
undergo sequential changes in morphology (Stein et al
1980, 1982). Activated lymphoid cells, which appear to
be memory cells (Jelinek and Lipsky 1987, Gray et al
1986) , migrate from the mantle zones towards the de¬
veloping germinal centres. Initially in the germinal
centres proliferating centroblasts are predominant.
Subsequently centrocytes appear and the germinal centre
can be morphologically separated into light and dark
zones, the centroblast derived centrocytes residing
predominantly in the light zone (Stein et al 1980,
1982). Centroblasts later disappear. Germinal centre
cells show phenotypic differences from mantle zone and
primary follicle cells. They do not or only weakly
express IgD and CD21 and have acquired CD10 and CD38
(Hsu and Jaffe 1984).
As well as B-cells germinal centres contain follicular
dendritic reticulum cells (DRCs) (Stein et al 1980,
1982) which probably function as long term antigen
presenting cells. Germinal centres are believed to be
the major source of memory cells in a secondary re¬
sponse (Klaus et al 1980, Coico et al 1983) . Memory
cells in turn enrich the mantle zones of B-cell folli¬
cles (Klaus and Kunkl 1981).
In vitro studies suggest that activation of peripheral
blood, lymph node and tonsillar derived lymphocytes
results in blast transformation and differentiation to
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Ig secreting cells. It appears that the microenviron-
ment within germinal centres is such that differentia¬
tion is promoted along the line for production of
memory cells rather than for Ig secretory cells. DRCs
may be the important cell in the control of this di¬
rected differentiation (Heinen and Tsunoda 1987).
1.2.2.2. Marginal Zone Cells and Centrocyte-like Cells
A number of experimental and immunohistological inves¬
tigations have led to the belief that a population of B
lymphocytes exists in the marginal zone of the spleen
and lymph nodes which are different from the recircu¬
lating and mantle zone lymphocytes. This population
which is CD5 negative is surface IgM positive but
surface IgD negative. Surface IgD negative follicular
germinal centre B-cells develop in animals lacking
marginal zone cells (Gray et al 1986, MacLennan et al
1985) whereas marginal zone cells can develop in rats
treated from birth with anti-IgD but surface IgD nega¬
tive follicular cells fail to develop (Bazin et al
1982). The marginal zone lymphocyte may be important
in the response to thymus independent antigens (MacLen¬
nan et al 1982, Gray et al 1985).
Phenotypically the centrocyte-like cell, marginal zone
cell and monocytoid B-cell are similar expressing
surface IgM, CD22 and CD21 but not CD5, CD23 or IgD
(Gray et al 1982, Sheibani et al 1985, Spencer et al
1985,1986). They therefore may be a related subpopula-
tion of B-cells perhaps committed in a differentiation
pathway outwith germinal centres.
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1.2.2.3 CD5 Positive Lymphocyte
A CD5 positive small lymphocyte makes up a significant
population of fetal primary follicle calls (Bofill et
al 1985) . In adults, however, this population is much
reduced and only about 5% of lymph node B-cells are CD5
positive, most being confined to the edge of germinal
centres (Caligaris-Cappio 1982). This pool of CD5
positive lymphocytes is polyclonally expanded in sever¬
al autoimmune disorders including rheumatoid arthritis
and CD5 positive B-cells may be important in the pro¬
duction of autoantibodies (Casali et al 1987, Hardy et
al 1987) .
1.2.3 Terminal Differentiation
Plasma cells are the end stage of B-cell differentia¬
tion and are the predominant cells involved in Ig
secretion. Plasma cells are present infreguently in
germinal centres (Isaacson et al 1980) but are present
in large numbers in medullary cords of lymph nodes, in
mucosa associated lymphoid tissue and in smaller num¬
bers in the bone marrow.
In vitro experiments show that following activation
with mitogens including anti-Ig and T cell derived
factors B-cells differentiate into immunoglobulin
secreting cells via large blast cells. This process of
differentiation is associated with alterations in
surface phenotype including loss of surface Ig, Class
II antigens and pan-B-cell markers and the gain of CD38
(Bhan 1981, Stashenko et al 1981, Boyd et al 1985a,
1986).
It has been postulated that there are at least two
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routes available in vivo for plasma cell production
(Lennert 1978, Weissman et al 1978):- one, that leads
to IgM production, is linked to the primary humoral
immune response whereas that of the secondary immune
response involves clonal expansion by germinal centres
and immunoglobulin isotype class switching which in¬
volves further immunoglobulin heavy chain gene rear¬
rangement (Cooper 1987). Differentiation to plasma
cells occurs in the medullary cords (Nieuwenhius and
Keuning 1974) and in marginal zones to T independent
antigens or in tissues after circulating (MacLennan
and Gray 1986).
In vivo a number of morphologically different forms of
"plasma cells" are seen including lymphoplasmacytoid
cells, with morphology between small lymphocytes and
plasma cells, plasmablasts and immunoblasts (Lennert
1978, Weismann et al 1978, Harris and Bahn 1985).
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1.3 THE RELATIONSHIP OF B-CELL PHENOTYPE TO ACTIVATION
GROWTH AND DIFFERENTIATION
The clonal expansion and differentiation of B-cells
appears to be distinct and depends upon the presence of
differing cytokines in the microenvironment (Muraguchi et
al 1985a) . Following antigen stimulation B-cell prolifer¬
ation will also result in the expansion of antigen spe¬
cific memory cells. B-cells may be activated to divide
without maturing to Ig secretion (Marujama et al 1983,
Isakson and Simpson 1984) and can mature without divid¬
ing (Neckers et al 1985). Therefore, following activa¬
tion, B-cells have a choice of either becoming memory
cells or differentiating to plasma cells. Helper T-cells
have an obligatory role in antibody responses against
most antigens with current concepts being those of a two
step theory of lymphocyte activation. The first step
reguires cross-linking of surface Ig on resting B-cells
which results in entry of into the cell cycle (Cambier
and Ransom 1987) and the expression of new surface mole¬
cules, many of which are functional receptors (Jelenik
and Lipsky, 1987). The second step is provided by helper
T-cells which secrete a number of lymphokines including
interleukin (IL) 2, IL4, IL5, IL6, gamma interferon and
other B cell growth and differentiation factors (Kishimo-
to 1985, Lee et al 1986, Yokata et al 1986, O'Garra et al
1988) .
Resting B-cells can be activated in vitro by a number of
means eg. specific antigen, cross-linking of surface Ig
and phorbol ester (Cambier et al 1982, Kuritani and
Cooper 1983, Suzuki et al 1985). Activation can be meas¬
ured by a number of ways, including alterations in cyto¬
plasmic calcium, RNA synthesis and increase in cellular
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DNA (Munroe and Cambier 1983, Cambier et al 1985, Kehrl
et al 1985). Such techniques have identified a number of
surface antigen changes which occur as B-cells are
activated and enter the cell cycle (Figure 1.2, page 16).
Three distinct activation stages are available to human
B-cells before they enter the cell cycle (Gordon and Guy
1987, 1988). The first stage is defined by the acquisi¬
tion of CD23 and the antigen recognised by the MCA
BK19.9. This is termed GOA. The second stage GOB is
recognised by increased binding of acridine orange to
DNA. Truly resting, deeply quiescent lymphocytes devoid
of activation antigens are in a stage termed GOQ. The
progression from GO - G1 is associated with cellular
enlargement RNA synthesis and new protein expression with
increased expression of DP, DQ and DR antigens (Kehrl et
al 1985) . B-cells in early G1 express 4F2 but not CD71
and have lost IgD (Kehrl et al 1984a,b). As cells
progress through Gl, 24-36 hours after stimulation, CD71
appears and CD21 decreases (Smeland et al 1985, Boyd et
al 1985a,1986). CD25 is expressed early in Gl and main¬
tained throughout the cell cycle whereas CD30 is not
expressed until G2 (Walker and Gordon 1987).
There are a number of points in the cell cycle at which
activated cells may be arrested and these appear in GO,
Gl and G2 (Gordon and Guy 1988, Melchers and Anderson
1986) . The presence or absence of surface membrane
molecules which interact with cytokines and ligands at
these points would be likely candidates for the control
of B-cell proliferation and differentiation.
Many of the molecules on resting B lymphocytes such as
CD20, CD21 and CD22 have activity in promoting B-cell
proliferation (Frade et al 1985b, Nemerow et al 1985,
Golay et al 1985, Pezzutto et al 1987c, vide infra).
Activation results in expression of surface receptors
for B-cell growth factors e.g. IL4 (Cambier and Ranson
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1987) . CD2 3 is a receptor for low mol wt BCGF (Swendeman
and Thorley-Lawson 1987). Anti CD23 MCA and low mol wt
BCGF both down-regulate CD2 3 expression and it is possi¬
ble that loss of CD23 by activated cells may facilitate
differentiation rather than proliferation (Kikutani et al
1986b). IL2 promotes growth and differentiation of B-
cells (Muraguchi et al 1985a, Nakagawa et al 1985).
Progression of B-cells through the cell cycle requires
IL2 (Gordon et al 1986a). A number of other factors
including IL4, IL5 and IL6 induce proliferation and
terminal differentiation of B-cells to Ig secreting
cells (Kishimoto 1985, Lee et al 1986, Yokata et al 1986,
O'Garra et al 1988) however the natural receptors for
these and other factors involved in control of B-cell
growth and differentiation have not yet been identified.
Proliferation is important for B-cell differentiation to
Ig secreting cells over and above that necessary to
expand the number of antigen-reactive cells (Jelenik and
Lipsky 1987). It has been shown however that in some
circumstances small lymphocytes may mature into Ig
secreting cells without proliferation (Anderson and
Melchers 1974, Neckers et al 1985). Ig secretion can also
occur in an actively proliferating cell population
(Jelinek and Lipsky 1983). Phenotypically recognised
subpopulations of B cells (eg. CD21+ and CD21-) respond
differently to activation and differentiation factors
(Anderson et al 1985, Boyd et al 1985a) suggesting dif¬
ferent requirements are necessary for proliferation or
differentiation at certain stages of B-cell maturity.
The phenotypic changes which occur following terminal B-
cell differentiation in-vivo and in-vitro are loss of
pan-B-cell and MHC Class II antigens and gain of CD38 as
previously described.
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Figure 1.2 - Changes of antigen expression by B-cells as
they enter and transit the cell cycle.
16
1.4 STRUCTURE FUNCTION AND DISTRIBUTION OF B-CELL SURFACE
ANTIGENS
Leucocytes express a large number of molecules on their
surface membranes which are important for cell-cell
interactions , responses to molecules such as antigen and
various cytokines which may induce activation, prolifera¬
tion or differentiation.
The identification of two distinct lymphocyte popula¬
tions: the antibody producing B-cell lineage and T-cells
allowed the production of allo-antisera which recognised
further antigens expressed differentially by the two
populations (Raff et al 1969, 1970), however it was not
until the late seventies that the use of monoclonal
antibody technology developed by Milstein and Kohler
(1975) resulted in an explosion of the number of anti¬
gens which could be recognised on human lymphocytes.
Initially the focus was on T-cells (Reinherz et al 1979,
Reinherz and Schlossman 1980) but a number of groups also
worked on the production of antibodies which would define
B-cells (Ritz et al 1980, Stashenko et al 1980). Since
those early days a large number of MCA have been produced
against leucocyte antigens. International workshops have
been held regularly since 1982 to standardise the charac¬
terisation and classification of these leucocyte markers
(Bernard et al 1984, Reinerz et al 1986, McMichael et al
1987). By the summer of 1989 the fourth International
Workshop on Human Leucocyte Differentiation Antigens had
been held, adding a further 35 new cluster determinants
(CDs) and subclusters to those previously defined (Knapp
et al 1989). A total of 78 clusters and subclusters are
now recognised. Many of the antigens have been defined
biochemically and genetically. The function of some and
their natural ligands are also being discovered. Of the
defined leucocyte antigens seven (CD19, CD20, CD21, CD22,
CD40, CD72 and CD77) are specific for B-cells while some
17
antigens are shared between B-cells and other leucocytes
(eg CD23, CD24, CD25, CD37, CD39, CD73, CD76, and CD78)
(Knapp et al 1989). The Leucocyte Differentiation Antigen
nomenclature includes the transferrin receptor (CD71) but
does not include immunoglobulin nor MHC Class II anti¬
gens .
The antigens studied during the project reported in this
thesis were limited by the availability of antibodies
against B-cell markers during the course of the project.
Only those antigens which were studied will be discussed
further (see Table 2.3, page 46). They have been seperat-
ed into five groups taking into account the available
published data on their expression by normal B-cells.
Immunoglobulin and MHC Class II antigens while being
recognised as pan-B-cell antigens have been grouped
seperately from antigens assigned CD numbers at the
recent workshops on Human Leukocyte antigens. 'Pan-B'-
cell antigens (CD19, CD20, CD22 and CD45R) are those
antigens expressed early in B-cell ontogeny continuously
until a pre-plasma cell stage of differentiation. The
•restricted' group (CD5, CD9, CD10 and CD38) are those
antigens which are believed to be expressed only at
certain points of B cell maturation or are expressed by
subsets of cells. Included in the 'activation-associated*
group (CD21, CD23, CD25, CD30, CD71 and 4F2) were anti¬




The CD19 antigen is a glycoprotein of approximately 95
kDa with three extracellular Ig-like domains having
strong homologies to human Ig C or V regions (Stamenkovic
and Seed 1988b). The antigen internalises rapidly after
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being bound by MCA (Uckun et al 1988b) and appears to
act as a receptor which regulates cytoplasmic calcium
concentrations (Pezzutto et al 1987 afb). It may function
via regulation of intracytoplasmic calcium concentration
to control B-cell proliferation (Clark and Ledbetter
1989) .
CD19 is a very early marker of B-cell differentiation
being expressed by pre-B-cells in fetal liver (Uckun et
al 1988a). It is expressed by mature B-cells (Nadler et
al 1983, Meeker et al 1984) and is present on resting and
both in-vivo and in-vitro activated B-cells (Boyd et al
1986, Freedman et al 1986, Schwartz et al 1986). It is
lost during terminal differentiation to plasma cells
(Nadler 1986).
CD20
The CD20 antigen consists of major 35 kDa and minor 37
kDa non-glycosylated phosphoproteins (Valentine et al
1987a, Moldenhauer et al 1987). Following activation by
phorbol ester CD20 is hyperphosphorylated and interna¬
lised (Valentine et al 1987b). Interaction of MCA with
CD20 does not cause alterations in intercellular calcium
concentrations (Tedder et al 1986a, Smeland et al 1987).
Anti-CD20 MCA have been produced which are either inhibi¬
tory to or promote B-cell activation. The anti-CD20 MCA
B1 inhibits proliferation and differentiation of B-cells
stimulated with either anti-Ig or EBV (Tedder et al
1985b, Golay et al 1985). Stimulatory anti-CD20 MCA cause
dense tonsillar B-cells to proliferate and are co-
stimulatory with either anti-Ig and low-molecular weight
BCGF (Clark et al 1985, Clark and Ledbetter 1986) in¬
creasing expression of C3d receptors (CD21), MHC Class II
molecules and c-myc proto-oncogene (Clark et al 1985,
Clark and Ledbetter 1986, Smeland et al 1985). The inhib¬
itory action of anti-CD20 MCA prevents DNA synthesis but
not the development of a number of activation associated
changes such as increase in IL2 receptors, cell enlarge-
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ment or RNA synthesis (Tedder et al 1986a).
CD20 is expressed by most B-cells from blood and lymphoid
tissue (Stashenko et al 1980) but many pre-B-cells which
are cytoplasmic mu, CD19 and CD22 positive are CD20
negative (Nadler 1986). It is present on both resting and
activated B-cells but is lost prior to terminal differ¬
entiation to plasma cells (Stashenko et al 1980, Boyd et
al 1986).
CD22
CD22 is a phosphorylated heterodimer with noncovalently
linked chains of about 130 and 140 kDa (Schwartz et al
1986, Boue and Lebien 1988).
MCA to CD22 augment entry into the cell cycle as measured
by RNA synthesis and proliferation of B-cells (Pezzutto
et al 1987c, 1988) . CD22 negative cells are incapable of
mobilising calcium following treatment with anti-Ig
(Pezzutto et al 1988).
CD22 is expressed early in B-cell ontogeny being found in
the cytoplasm of TdT positive and pre-B-cells at approxi¬
mately the same time as CD19 (Campana et al 1985, Ling et
al 1987) and is expressed by mature B-cells in lymphoid
tissues (Mason et al 1987). Following activation of
lymphocytes in-vitro there is a transient increase of
CD22 expression and subsequent loss with differentiation
(Pezzutto et al 1988).
CD45R
CD45 is the leucocyte common family, a group of high
molecular weight glycoproteins expressed at the surface
of leucocytes and precursors (Thomas 1989). The gene for
the leucocyte common antigen (LCA) is present on chromo¬
some 1 and the different forms are believed to be pro¬
duced by differential splicing of three exons to poten-
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tially generate eight mRNAs (Thomas 1989) . LCA has exte¬
rior, transmembrane and cytoplasmic domains. Four major
species are recognised with molecular weights of about
220, 205, 190 and 180 kDa. These differ in protein se¬
quence and carbohydrate structures of the external do¬
main. MCA which react with LCA may recognise common
epitopes (CD45) or restricted epitopes (CD45R) (Cobbold
et al 1987). Restricted epitopes have been further sepa¬
rated into CD45RA, expressed by the high molecular weight
form and CD45RO, expressed by the low molecular (180 kDa)
form. F8-11-13 the MCA used in this study recognises
CD45RA (Norton and Isaacson 1989).
Antibodies to both the common and restricted epitopes of
CD45 inhibit B-cell proliferation induced by anti-IgM and
T-cell replacing factors (Mittler et al 1987). Inhibition
is maximal on small resting cells and appears to inter¬
fere with an early stage of activation. CD45 may also
regulate progression and maturation signals to lympho¬
cytes (Clark and Ledbetter 1989).
All B-cells express the 220 kDa form of CD45, CD45RA,
(Thomas 1989). It appears very early in B-cell develop¬
ment probably preceeding immunoglobulin gene rearrange¬
ment (Kincade 1987) and is present on all peripheral B-
cells but is lost with differentiation to plasma cells
(Dalchau and Fabre 1981, Salter et al 1985, Kincade
1987) .
1.4.2 Restricted B-cell markers
CD5
CD5 is a 67 kDa glycoprotein (Ledbetter et al 1981, Jones
et al 1986) . The function of CD5 has not been fully
evaluated. Anti-CD5 antibodies enhance IL2 production
and proliferation responses by T-cells in mixed lympho-
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cyte cultures (Hollander et al 1981, Stanton et al 1986).
They act by mobilising cytoplasmic calcium and up-regu¬
lating signalling through the CD3 receptor (June et al
1987) .
CD5 is recognised as a pan-T-cell marker but is also
expressed by surface Ig positive B chronic lymphocytic
leukaemia (CLL) cells (Martin et al 1980, Royston et al
1980) and a population of fetal and adult normal B-cells
(Caligaris-cappio 1982, Gobbi 1983). CD5 positive normal
B-cells are primarily responsible for autoantibody pro¬
duction (Casali et al 1987, Hardy et al 1987). It is
possible that CD5 positive B cells represent a distinct
subpopulation although it has been suggested that CD5
expression may be induced on B-cells by phorbol esters
(Miller and Gralow 1984).
CD9
CD9 was assigned to an antigen of mol wt 24 kDa at the
first workshop on leukocyte antigens (Bernard et al
1984). It has subseguently been shown to have protein and
serine kinase activity (Seehafer et al 1984, Zipf et al
1986). Antibodies to CD9 augment the response of B-CLL
cells to phytohaemagluttinin (PHA) (Briggs et al 1987).
It is expressed by a number of non-haemopoietic and
haemopoietic cells including subsets of B-cells, common
acute lymphoblastic leukaemia antigen (cALLA) positive
lymphoblastic leukaemia cells and tonsil follicle cells
(Ling et al 1987).
CD10
CD10 is a glycoprotein of approximately 100 kDa. Altera¬
tion of the carbohydrate component produces a number of
variants (Braun et al 1983, Pesando et al 1980, McCormack
et al 1986). The antigen was initially defined by Greaves
et al in 1975 as the common acute lymphoblastic leukaemia
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antigen (cALLA). The function of this marker is unknown.
CD10 is expressed by pre-B-cells in foetal liver (Hokland
et al 1983).In peripheral lymphoid tissues it is ex¬
pressed by germinal centre cells but is absent from
mantle zone cells (Hsu and Jaffe 1984).
CD38
CD38 was assigned to a 45 kDa glycoprotein at the second
workshop on leukocyte antigens (Reinherz et al 1986) . The
function is unknown.
It is not expressed by resting B cells but is expressed
by progenitor T and B cells (Bhan et al 1981), germinal
centre cells and plasma cells (Hsu and Jaffe 1984).
1.4.3 Activation Associated Antigens
CD21
The CD21 antigen is a non-phosphorylated 140 kDa glyco¬
protein (Oettengen et al 1983) which has been identified
as the CR2, C3d receptor (Iida et al 1983, Weis et al
1984). It is also the receptor for EBV (Fingeroth et al
1984, Frade et al 1985a). The CD21 antigen internalises
when bound to MCA or EBV (Tedder et al 1986b) . Anti-CD21
MCA stimulate proliferation of normal resting B-cells
(Frade et al 1985b, Wilson et al 1985, Nemerow et al
1985) and may act by causing both membrane depolarisation
and increasing cytoplasmic calcium levels (Rabinovich et
al 1987).
CD21 is absent or present in very low amounts on immature
B-cells (Campana et al 1985, Tedder et al 1984). Only 60
per cent of peripheral blood and bone marrow B-cells
express CD21 and the antigen is present in highest
amounts on mature B-cells in lymphoid tissue, predomi¬
nantly mantle-zone cells (Clark and Einfield 1986, Mason
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et al 1986, Ling et al 1987). After activation in-vitro
by anti-Ig or phorbol ester, B-cells loose CD21 simulta¬
neously with IgD (Boyd et al 1985a, 1986, Freedman et al
1986). CD21 is absent from terminally differentiated B-
cells (Ling et al 1987).
CD23
CD23 is a glycoprotein which exists in two forms. The
membrane bound form has a molecular weight of approxi¬
mately 45 kDa (Thorley-Lawson et al 1986). The soluble
form comprises a 33 kDa glycoprotein which is probably
released from the larger molecule by a protease dependent
pathway (Kikutani et al 1986a,b). CD23 is a low affinity
receptor for IgE (Kikutani et al 1986a, Bonnefoy et al
1987). The soluble CD23 molecule binds to IgE and has
been found to have B-cell growth factor activity (Swende-
men and Thorley-Lawson 1987,1988). Anti-CD23 MCA have
BCGF-like activity and are costimulatory with phorbol
ester in inducing B-cell proliferation (Gordon et al
1986b, 1987). The CD23 antigen appears to be closely
associated with MHC Class II DR (but not DP or DQ) on the
surface membrane (Bonnefoy et al 1988).
CD23 is either absent or present in very small amounts on
resting B-cells but appears rapidly after activation and
precedes entry into the cell-cycle by GO B-cells (Walker
et al 1986). In-vivo CD23 is expressed by mantle zone
cells but not by germinal centre B-cells in peripheral
lymphoid tissue (Ling et al 1987).
CD25
The CD25 antigen consists of two non-covalently linked 55
and 75 kDa polypeptides (Smith 1987, 1989) and is the
receptor for IL2 (Leonard et al 1982). Both polypeptides
are capable of binding IL2 but with low affinity and it
is only when both proteins are associated that a high
affinity receptor is formed (Smith 1989). Anti-Tac MCA
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recognise the low molecular weight protein (Leonard et al
1982) .
IL2 promotes T-cell growth and functions to enhance B-
cell growth and differentiation (Muraguchi et al 1985b,
Nakagawa et al 1985) . It appears to function late in the
cell cycle probably in S, G2 or M (Mingari et al 1985)
acting as a progression signal.
CD3 0
CD30 is an 105/120 kDa glycoprotein which was initially
defined as an antigen expressed by Hodgkin and Reed-
Sternberg cells (Schwab et al 1982). It is absent from
resting but present on activated lymphocytes (Stein et al
1985). Expression by B-cells occurs following stimula¬
tion by phorbol ester but not until G2, late in the cycle
(Walker and Gordon 1987). Although expression appears to
be related to activation the function is unknown.
In normal lymphoid tissue expression is limited to a
population of large blasts in the interfollicular area
(Palleson and Hager 1987) and a population of blasts
localised around B cell follicles, in some instances at
the rim of germinal centres (Schwab et al 1982).
CD71
The transferrin receptor was assigned CD71 at the fourth
International Workshop on Leukocyte Differentiation
Antigens. It is a transmembrane glycoprotein with a
molecular weight of 180 kDa, being comprised of two
disulphide bonded 90 kDa subunits (Newman et al 1982).
Its expression is associated with cell activation and
proliferation (Trowbridge and Omary 1981). Anti CD71 MCA
inhibit lymphocyte proliferation (Mendolsohn et al 1983).
In normal lymphoid tissue CD71 is expressed by germinal
centre cells, macrophages and variable numbers of cells
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in the paracortex (Hsu and Jaffe 1984).
4F2
The monoclonal antibody 4F2 (Haynes et al 1981) recog¬
nises the heavy subunit of a heterodimeric polypeptide
complex comprising a glycoprotein of approximately 80 kDa
and a disulphide linked light subunit of approximately 40
kDa (Hemler and Strominger 1982). The function of the
antigen is unknown. It is expressed early in G1 by pro¬
liferating lymphocytes but is not expressed by resting
lymphoid cells (Kehrl et al 1984a,b). 4F2 partially
inhibits lymphocyte proliferation induced by mitogens
(Haynes et al 1981).
1.3.4 MHC Class II Molecules
MHC Class II molecules are a group of heterodimers con¬
sisting of alpha and beta chains of mol wt 34 kDa and 29
kDa respectively (reviewed by Giles and Capra 1985). They
are encoded by genes in the MHC region on the short arm
of chromosome 6. These genes are organised in three loci
- DR, DP and DQ, each locus comprising several genes. The
beta chains are highly polymorphic. Class II antigen
expression is important for cellular interactions in the
immune response.
MHC Class II molecules are expressed by cells of the
lympho-reticular system and also by other tissues (Daar
et al 1984, Guy et al 1986). Expression may be induced by
gamma interferon (Shaw et al 1985). In normal lymphoid
tissue B-cells, macrophages and a proportion of paracor-





Since Thomas Hodgkin published his treatise on primary
lymphoid malignancy in 1832 understanding and classifica¬
tion of malignant lymphoma has changed markedly (reviewed
by Banks and Berard 1977, Nathwani and Winberg 1983).
Virchow distinguished lymphoma from leukaemia and in 1871
Billroth used the term malignant lymphoma. In 18 65 Wilks
divided lymphoma into two groups, separating Hodgkin's
Disease from non-Hodgkin's Lymphoma. Classifications of
non-Hodgkin's Lymphoma developed initially on a few
fundamental concepts, e.g. neoplasms composed of small
non-replicating lymphocytes were recognised as a favour¬
able group, whereas those with atypical lymphocytes with
mitoses were less favourable. Cases composed of large
cells were considered non-lymphoid, i.e. stem cell or
histiocytic in origin. Sequential classification systems
of NHL such as those of Robb-Smith, Gall and Mallory,
Rappaport and Gall and that of Rappaport' s in 1966
(Rappaport 1966) were clinically valuable in that morpho¬
logically recognisable categories were shown to have
prognostic significance and were of great benefit to
clinicians in their management of patients. Nevertheless
since their publication there have been great strides in
the understanding of lymphocyte physiology, the organisa¬
tion of lymphoid tissue and its division into T and B-
cell compartments which highlighted a number of inaccura¬
cies in the Rappaport system which had become widely
used. Newer classifications have been introduced in an




Immunological and morphological analyses have led to a
variety of new schemes for pathologic classification of
non-Hodgkin1s lymphoma. Such classifications were based
in part on the belief that NHL are monoclonal prolifera¬
tions of lymphoid cells which were blocked at a particu¬
lar stage of differentiation or are due to cells being
activated (Lukes and Collins 1974) with resultant in¬
creased and uncontrolled proliferation. Lymphomas would
therefore be expected to show similarities to cells of
the normal immune system. In the early seventies Stein
and Lennert showed that the majority of non-Hodgkin's
lymphomas were derived from B-cells including the large
cell types - reticulum cell sarcoma and histiocytic
lymphoma (Stein et al 1972,1974). Lymphomas of nodular or
follicular pattern were shown to be neoplastic counter¬
parts of germinal centre cells (Jaffe et al 1974). Numer¬
ous other studies have shown morphological and immuno¬
logical similarities between groups of lymphomas and
normal nodal and extra-nodal lymphoid cells (Stuart and
Habeshaw 1976, Habeshaw et al 1977, 1979, Lennert 1978,
Weissman et al 1978, Stein et al 1980).
Some of the new classifications such as those of the
World Health Organisation (Mathe et al 1976), the British
Lymphoma Group (Bennett et al 1974) and Dorfman (Dorfman
1974) were based mostly on morphological features and
comparison with normal counterparts. However both the
Kiel (Lennert 1978, Stansfeld et al 1988) and the Lukes
and Collins (1974) classifications emphasised immunolog¬
ic cell type in addition to morphology. The Kiel classi¬
fication (Table 1.1) has the additional advantage of
accepting that tumours of similar histological type could
be either of T or B-cell lineage, the classification of
Lukes and Collins asserting that phenotypic diversity
could be identified by cytomorphometry alone. Neverthe-
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less the importance of different histological groups with
clinical relevance was appreciated in these new classifi¬
cations and low and high grade categories with better and
poorer clinical outcomes respectively were recognised.
In an effort to resolve the controversy over classifica¬
tion of non-Hodgkin's lymphoma the National Cancer Insti¬
tute sponsored a large multi-institutional, international
comparison study (Rosenberg 1982). Over 1000 cases with
long term clinical follow-up were reviewed by a panel of
pathologists and the value and reproducibility of six
major classifications Rappaport, Lukes and Collins,
Dorfman, British Lymphoma Group, Kiel and WHO, were
assessed. Analysis showed all the classifications to be
of value and comparable but none was clearly superior.
The panel believed however that a common terminology was
required to allow comparisons of results of clinical
trials throughout the world and proposed a Working Formu¬
lation of NHL for clinical usage (Table 1.2) based upon
simple morphological criteria. Being based purely upon
morphology the Working Formulation has been criticised in
that it lumps together some entities which are biologi¬
cally distinct and takes no consideration of the cell of
origin.
1.4.3 Prognostic Factors
Classification of NHL by morphology allows separation
into different groupings which have clinical relevance
(Rosenberg 1982). However within these groupings differ¬
ences in clinical outcome are apparent. Most low grade
tumours are indolent but incurable and will lead to death
after a number of years (Portlock 1983) whereas patients
with high-grade tumours given aggressive chemotherapy
approximately half will obtain long-term (>2 years)
disease-free remission, the remainder not surviving for
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much over 1 year (De Vita et al 1988).
A number of clinical and biological parameters have been
studied in an attempt to more accurately predict the
behaviour of these lesions. Of the various clinical
parameters studied systemic symptoms (such as fever,
weight loss and night sweats) and bone marrow involvement
(Bloomfield et al 1974), sex and stage (Leonard et al
1983), tumour bulk (Cabanillas et al 1979) and age
(Horwich and Peckham 1983) have been shown to be of
prognostic value. In high-grade NHL the presence of B
symptoms (Fisher et al 1980, Horwich and Peckham 1983),
and disseminated disease (Bloomfield et al 1979) are
associated with poorer survival.
The biological parameters studied include assessment of
proliferation rates by a number of techniques. Thymidine
labelling of NHL by a number of groups has been shown to
provide data of prognostic significance, high labelling
indices being associated with poor survival (Costa et al
1981, Kvaloy et al 1985, Holte et al 1987). The numbers
of cells in S-phase of the cell-cycle as measured by flow
cytometry may be associated with survival (Roos et al
1985) although this is not a consistent finding (Morgan
et al 1986) . The relatively simple method of assessing
proliferative activity by counting mitotic fingers has
been shown by some workers to be of prognostic signifi¬
cance (Evans et al 1978) although this is not a consist¬
ently reported observation (Warnke et al 1982, Ellison et
al 1987). The MCA Ki67 which recognises a proliferation
associated nuclear antigen (Gerdes et al 1984) may pre¬
dict a poor prognostic group of low-grade NHL (Hall et al
1988). Immunophenotypic studies have been included in
some studies but have shown conflicting results. A "null"
cell phenotype appears associated with poor survival
(Bloomfield et al 1979). In a number of series T-cell NHL
are more aggressive than their B-cell counterparts
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(Lindemalm et al 1983, Brown et al 1989) whereas similar
clinical behaviour is seen in other series (Cossman et al
1984, Horning et al 1986). The non-lineage specific
markers CD71 (transferrin recepter) and 4F2 both of which
are associated with lymphoid activation and proliferation
have been reported to be associated with prognosis
(Habeshaw et al 1983, Pileri et al 1984, Holte et al
1987). Analysis of chromosomal abnormalities may also
provide clinically useful information, certain deletions
and duplications being associated with poor survival in
high-grade NHL (Yunis et al 1989).
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Table 1.1 Kiel Classification of Non-Hodgkin1s Lymphoma
(B-cell type).
Low Grade















Table 1.2 Working Formulation of Non-Hodgkin's Lymphoma.
Low Grade
A. Malignant lymphoma, small lymphocytic:- consistent
with CLL, plasmacytoid.
B. Malignant lymphoma, follicular:- predominantly small
cleaved cell, diffuse areas, sclerosis.
C. Malignant lymphoma, follicular:- mixed small cleaved
and large cell, diffuse areas, sclerosis.
Intermediate Grade
D. Malignant lymphoma, follicular:- predominantly large
cells, diffuse areas, sclerosis.
E. Malignant lymphoma, diffuse:- small cleaved cell,
sclerosis.
F. Malignant lymphoma, diffuse:- mixed small and large
cell, sclerosis, epithelioid cell component.
G. Malignant lymphoma diffuse:- large cell- cleaved cell,
non-cleaved cell, sclerosis.
High Grade
H. Malignant lymphoma, large cell, immunoblastic:-
plasmacytoid, clear cell, polymorphous, epithelioid cell
component.
I. Malignant lymphoma lymphoblastic:- convoluted cell,
non-convoluted cell.
J. Malignant lymphoma small cleaved cell:- Burkitt's,
follicular areas.
Miscellaneous including extramedullary plasmacytoma.
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CHAPTER 2 MATERIALS AND METHODS
2.1 CASES
Cases included in this study were sequential cases of B-
cell NHL diagnosed in the immunopathology laboratory
Edinburgh University Pathology Department, during the
period August 1984 to January 1987 inclusive and all
cases of B-cell NHL diagnosed in the department during
the period July 1982 to July 1984 in which tissue had
been snap frozen in liquid nitrogen and stored at -70°C.
Cases were diagnosed as B-cell lymphomas if they ex¬
pressed one or more pan-B cell antigens and/or expressed
monotypic immunoglobulin light chain. T-cell lymphomas,
identified by expression of T-lineage specific antigens
(CD2, CD3 and CD7) were excluded (Krajewski et al 1988).
2.2 TISSUE COLLECTION AND HANDLING
Tissue was received fresh from the operating theatre.
Representative portions were taken for cryostat sections
and for fixation in 4% buffered formaldehyde and paraf¬
fin sectioning. In all cases where sufficient tissue was
available material was taken for snap-freezing in liquid
nitrogen and storage at -70°C.
2.3 IMMUNOHISTOCHEMICAL STAINING
Cryostat sections were cut at 3-4 microns from either
freshly frozen material or from tissue stored at -70°C,
allowed to air dry at room temperature for 30 min before
fixing in 100 per cent acetone for 20 min.
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2.3.1 Indirect Immunoperoxidase
The procedure is summarised in Table 2.1. Sections were
washed in Tris buffered saline (TBS) (0.5M tris, 1M HCL,
pH7.6) followed by TBS containing 20% normal rabbit serum
(NRS) for 10 min. Excess fluid was then tipped off and 50
ul of the primary antibody diluted in TBS/NRS was added
and incubated in a wet box for 30 min. The slides were
then washed twice in TBS for 10 min, the area around the
sections wiped with a paper tissue and 50 pi of rabbit
anti-mouse Ig conjugated to peroxidase (Dako P-260)
diluted 1:20 in TBS/NRS added. Following 30 min. incuba¬
tion at room temperature in a wet box sections were
washed twice in TBS for 5 min. The area around the sec¬
tions was wiped dry with a tissue and the slide flooded
with freshly made substrate (lmg/ml diaminobenzidine in
0.02M tris HCL with 0.01M imidazole pH7.6). lOOyl of 1%
H202 was added to the substrate immediately before use
and the reaction stopped after 5 min by immersion in tap
water for 2 min. The slides were then counterstained in
haematoxylin, washed in water, briefly dipped in lithium
carbonate, before washing again. The slides were then
dehydrated through alcohol to xylene before being mounted
in Histomount.
Negative controls were included by omitting the primary
antibody. In the majority of cases small numbers of
immunoreactive neoplastic or residual normal lymphoid
cells were present which acted as intrinsic positive
controls. In the small number of cases where sections
were completely negative when stained with an antibody
the proceedure was repeated with the inclusion of a




The proceedure is summarised in Table 2.2. F(ab)2 anti¬
bodies at the appropriate dilution, conjugated to
fluorescein isothiocyanate (FITC) or tetraethylrhodamine
urothiocyanate (TRIC) were added directly to the sections
and incubated at room temperature for 20 min. Slides were
then washed twice in TBS for 5 min before being mounted
in glycerol-saline and viewed under ultra violet light
using a Leitz laborlux 12 microscope. Incident light was
provided by a HBO 50 watt mercury short arc lamp. For
FITC 450-490 nm exciting and 515 nm suppression filters
were used. 530-560 nm and 580 nm exciting and suppression
filters were used for visualising TRIC.
2.4 ANTIBODIES
The antibodies used, their source, specificity and dilu¬
tion used are shown in Table 2.3. At the outset of the
study HD37, SRFB6, MHM6 and Dako-Kil were not available
but were included at a later date. The antibodies used
were selected because of postulated reactivity with
antigens expressed by B-cells at different stages of in
vivo and in vitro activation and differentiation. They
were used at dilutions ascertained following titration
against normal lymph nodes to give optimal staining in
tissue sections of lymphoid cells in a manner consistent
with their previously documented reactivity and manufac¬
turers data sheets and with minimal background staining.
Anti-Iq
Anti-kappa, anti-lambda and anti-IgM antibodies were used
by immunoperoxidase on cryostat sections in all cases. In
addition in a number of other cases further staining for
Ig was carried out by immunofluorescence with TRIC conju¬
gated anti-kappa and anti-lambda and FITC conjugated
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antibody to kappa or lambda or mu, gamma, delta and alpha
heavy chains.
HD37
HD37 is an IgGl MCA which reacts with CD19 (Pezzutto et
al 1986, Nadler 1986). It detects primary and secondary
follicular and extrafollicular B-cells in tissue sec¬
tions .
B1
B1 is an IgG2 MCA which recognises CD20 (Nadler et al
1981, Nadler 1986). It reacts with greater than 95% of
peripheral blood and lymphoid tissue B cells (Stashenko
et al 1981).
Dako-B
Dako-B is an IgG2b MCA. It recognises CD22 (Nadler 1986)
and labels primary and secondary follicle cells and
isolated extrafollicular B-cells in cryostat sections of
lymphoid tissue (Mason et al 1987).
F8-11-13
F8-11-13 is an IgGl MCA which reacts with CD45R, the high
molecular weight restricted form of the leucocyte common
antigen (Dalchau and Fabre 1981, McMichael et al 1987).
It is expressed by primary and secondary follicular B-
cells and also by a subpopulation of T-cells (Dalchau and
Fabre 1981, Salter et al 1985).
Leul
Leul is an IgG2 MCA which recognises CD5 (Royston et al
1980, Bernard et al 1984). In normal lymphoid tissue it
reacts predominately with T-cells but a minor population
of mantle zone lymphocytes may also be positive (Caliga-
ris-Cappio et al 1982).
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FMC8
FMC8 is an IgG MCA which recognises CD9 (Bernard et al
1984, Zola 1987). It reacts with a proportion of pre-B-
cells and 45% of circulating B cells (Brooks et al 1982).
Dako-CALLA
Dako-CALLA is an IgGl MCA which reacts with the human
acute Lymphoblastic Leukaemia Antigen (Newman et al 1981)
designated CD10 (Bernard et al 1984). CD10 has been shown
to be expressed by germinal centre cells in reactive
lymphoid tissue (Hsu and Jaffe 1984).
OKTIO
OKTIO is an IgGl MCA which recognises CD38 (Bhan et al
1981, McMichael et al 1987). In tissue sections it stains
plasma cells (Bhan et al 1981) and germinal centre cells
but not mantle zone cells (Gobbi et al 1983, Hsu and
Jaffe 1984) .
S/RFB6
S/RFB6 is an IgGl MCA which recognises CD21 (Campana et
al 1985). It stains the majority of B-cells in mantle
zones and shows strong reactivity in germinal centres
(Campana et al 1985) .
MHM6
MHM6 is an IgG MCA which recognises CD23 (Ling et al
1987). It reacts weakly with a variable portion of mantle
zone cells and a subpopulation of DRCs in germinal cen¬
tres (Pallenson and Hager 1987, Mason et al 1986).
Dako-IL2R
Dako-IL2R is an IgGl MCA which reacts with CD25 the low-
molecular weight, 55kDa polypeptide component of the IL2
recepter (Leonard et al 1982, Reinherz et al 1986). In
peripheral lymphoid tissue Dako-IL2R labels a varying
proportion of lymphoid cells in T-cell zones and light
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zones of the germinal centre (Dakopatts data sheet).
Dako Kil
Dako Kil is an IgG3 MCA which reacts with the 105/120 KDa
glycoprotein designated CD3 0 (McMichael et al 1987) . In
normal lymphoid tissue Dako-Kil reacts with a small
population of large cells preferentially located around
B-cell follicles (Schwab et al 1982).
0KT9
0KT9 is an IgGl MCA which reacts with the transferrin
receptor, CD71 (Reinherz et al 1980, Knapp et al 1989).
In normal lymphoid tissue it reacts with germinal centre
cells and scattered cells outside follicles (Hsu and
Jaffe 1984). Most mantle zone cells are negative (Murray
et al 1984).
4F2
4F2 is an IgG2a MCA which recognises a disulphide linked
glycoprotein of unknown function expressed by macrophages
and proliferating lymphoid cells (Haynes et al 1981.
Kehrl et al 1984a,b).
L2 4 3
L243 is an IgG2 MCA which recognises a non-polymorphic
determinant of MHC Class II HLA DR (Lampour and Levy
1980, Brodsky 1984). In lymph nodes L243 reacts with
primary and secondary follicular B-cells and a variable
number of paracortical cells (Hsu and Jaffe 1984).
B7/21
B7/21 is an IgG3 MCA which recognises MHC Class II DP and
reacts in tissue sections with follicular B cells and a




LeulO is an IgGl MCA which recognises a determinant on
most but not all HLA Class II DQ molecules (Brodsky
1984). In lymph nodes it reacts with scattered cells of
the paracortex and all primary and secondary follicular
B-cells (Krajewski et al 1985).
Tu22
Tu22 is an IgG MCA which reacts with MHC Class II DQ
(Brodsky 1984). In lymph nodes it reacts with scattered
cells of the paracortex and all primary and secondary
follicular B-cells (Krajewski et al 1985) .
Leu 4
Leu 4 is an IgGl MCA which reacts with CD3 (Ledbetter et
al 1981). It is a pan-T-cell marker and does not react
with B-cells.
2.5 ASSESSMENT OF STAINING
Cells were scored as being positive if they showed cyto¬
plasmic or surface membrane staining. The pattern of
immunoglobulin staining and pan-B-cell staining was used
in conjuction with toluidine blue and H and E stained
sections to show the distribution of neoplastic and
reactive B-cells in the tissues studied. Those areas were
identified in serial sections and the cells assessed for
immunoreactivity with the other markers. Counterstaining
immunoperoxidase stained sections with haematoxylin
allowed additional information on the distribution and
type of cells staining. The number of cells staining was
assessed in a semi-guantitative manner using a four point
scale. The estimated population of malignant cells were
scored as >70% = 3+ (figure 2.1), approximately 30 - 70%
= 2 + (figure 2.2), approximately 5 -30% = 1+ (figure
2.3), approximately <5% = 0 (figure 2.4).
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Centroblastic lymphoma (LG no.1051) reacted with S/RFB6
(anti-CD21) showing no staining of tumour cells but
residual DRCs are positive. Scored as 0.
Figure 2.2
Immunoblastic lymphoma (LG no 620) stained with OKTIO
























Lymphocytic lymphoma (LG no 919) reacted with 0KT9 (anti-
CD71) showing a proportion of the cells staining. Scored
as ++.
Figure 2.4
Diffuse Centroblastic/centrocytic lymphoma (Case LG no
85) stained with F8-11-13 (anti-CD45R). The vast majority
of cells are positive. Scored as +++.
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2.6 PARAFFIN SECTION HISTOLOGY AND LYMPHOMA CLASSIFICA¬
TION
H and E stained sections of formalin fixed paraffin
embedded tissues were diagnosed by myself and Dr A S
Krajewski as part of the routine diagnostic service
provided by Edinburgh University Department of Pathology.
Cases were classified by consensus using the Kiel clas¬
sification (Lennert 1978, Stansfeld et al 1988) and the
Working Formulation (Rosenberg 1982) (see Tables 1.1 and
1.2). It is becoming evident that malignant lymphomas of
MALT have distinctive clinical and biological features
(Isaacson and Wright 1984, Isaacson and Spencer 1987).
Classifications of this group of tumours are beginning to
be developed (Isaacson et al 1988) but were not in gener¬
al use during the period of this study. Lymphomas of MALT
were therefore included with other NHL and classified by
Kiel and Working Formulation.
2.7 CLINICAL DATA
Clinical information was obtained from the clinical notes
of patients. Notes were obtained from 110 of the 148
cases phenotyped, but were not traced for the remainder.
Data was collected for age, sex, stage according to the
Ann Arbor classification (Carbonne et al 1971), bone
marrow involvement, therapy induction of remission and
survival.
Treatment was separated into two groups :- a) low grade
therapy included treatments which were given for pallia¬
tive purposes and included surgery, radiotherapy, cyclo¬
phosphamide, vincristine and prednisolone, b) high grade
therapy were those treatments which were potentially
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curative or able to induce long term remission and in¬
cluded CHOP+/-bleomycin, BACOD, MOPP, MVPP, CH1VPP, M-
PEEC, MCHOP+/-bleomycin.
Complete remission was defined as disappearance of all
disease present at the start of the therapy . Partial
remission was defined as a reduction in tumour bulk to
less than 50% whereas no reduction or reduction of less
than 50% were grouped as showing no remission.
Survival was calculated from the date of diagnosis to the
date of death or last follow-up. All patients on which
clinical data were available were included in the surviv¬
al analysis regardless of the type of treatment or cause
of death.
2.8 STATISTICAL ANALYSIS
Comparisons between groups i those positive or negative
for an antigen, were made by the Chi-square test. Surviv¬
al curves were estimated by the Algorithm of Lee and Desu
(Lee and Desu 1972) using SSPX software. Cox's propor¬
tional hazards regression model (Cox 1972) was used to
adjust the simultaneous effect of different prognostic
factors on survival.
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Table 2.1. Indirect Immunoperoxidase Method
1. Cut cryostat sections at 3-4 microns. Air dry for 30
min at room temperature.
2. Fix in 100 per cent acetone for 20 min.
3. Wash in TBS (10 min).
4. Wash in TBS/20% normal rabbit serum(NRS).
5. Add 50pl primary antibody diluted in TBS/NRS, incubate
in a wet box for 30 min at room temperature.
6. Wash twice in TBS (10 min).
7. Add rabbit anti-mouse Ig conjugated to peroxidase,
incubate in a wet box for 30 min at room temperature.
8. Wash twice in TBS (5 min).
9. Add lmg per ml diaminobenzidine /0.02M tris HCL/0.01M
imidazole (pH7.6) + lOOjul 1% H202 for 2 min.
10. Wash in tap water.
11. Stain with haematoxylin.
Table 2.2. Direct Immunofluorescence Method
1. Cut cryostat sections at 3-4 microns. Air dry for 30
min at room temperature.
2. Fix in 100 per cent acetone for 20 min.
3. Wash in TBS (10 min).
4. Add 5OjLil of antibody conjugate (IgH-FITC, K-FITC/L-
TRIC, or K-TRIC/L-FITC), incubate in a wet box for 20 min
at room temperature.
5. Wash twice in TBS (5 min).
6. Mount in glycerol-saline and view under UV light.
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Table 2.3 Antibodies used in this study
Antibody Dilution ig Specificity Source
Subclass Mol Wt/CD No.
Anti-Immunoglobulin
anti kappa 1:500 G1 kappa Dakopatts
anti kappa-FITC 1:20 G kappa Kallestad
anti kappa-TRIC 1:20 G kappa Kallestad
anti lambda 1:5 G1 lambda Dakopatts
anti lambda-FITC 1:20 G lambda Kallestad
anti lambda-TRIC 1:20 G lambda Kallestad
anti IgM 1:2000 G1 IgM Dakopatts
DA6127 1:20 G2 IgM K Guy
anti IgM-FITC 1:20 G IgM Kallestad
anti IgD 1: 50 G1 IgD Dakopatts
anti IgD-FITC 1:20 G IgD Kallestad
anti IgG 1:5000 G1 IgG Dakopatts
anti IgG-FITC 1:20 G IgG Kallestad
anti IgA 1:2000 G1 IgA Dakopatts
anti IgA-FITC 1:20 G IgA Kallestad
"Pan" B-cell
HD3 7 1:200 G1 40/CD19 Dakopatts
B1 1:10 G2 35/CD20 Coulter
Dako-B 1:10 G2b 135/CD22 Dakopatts
F8-11—13 1:1000 G1 220/CD45RA J Fabre
"Restricted" B-Cell
Leu 1 1:100 G2 65/CD5 BD
FMC8 1:20 G 24/CD9 H Zola
Dako Calla 1:5 G1 100/CD10 Dakopatts
OKTIO 1:40 G1 45/CD38 Ortho
"Activation-associated"
S/RFB6 1:10 G1 14 0/CD21 SAPU
MHM6 1:20 G 45/CD23 J Gordon
Dako-IL2-R 1:200 G1 55/CD25 Dakopatts
Dako-Kil 1:5 G3 116,126/CD30 Dakopatts
0KT9 1:10 G1 90/CD71 Ortho
4F2 1:20 G2a 40,80/NA ATCC
MHC Class II
L243 1:20 G2a DR ATCC
B7/21 1:10 G3 DP IS Trowbridcg
Leu 10/TU22 1:200/1: 10 Gl/G DQ BD/A Ziegler
"Pan" T-Cell
Leu4 1:100 G1 22 ,28/CD3 BD
BD = Becton Dickenson, NA = not allocated,
SAPU = Scottish Antibody Production Unit,
ATCC=American Tissue Culture Collection
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CHAPTER 3 PHENOTYPES OF B-CELLS IN REACTIVE PERIPHERAL
LYMPHOID TISSUE
3.1 INTRODUCTION
As discussed in Chapter 1 lymph nodes may be separated
anatomically into three main areas:- cortex, paracortex
and medulla (Van der Valk and Meijer 1988). B-cells are
present in primary and secondary follicles. Mantle zone
cells are believed to be resting cells while germinal
centre cells are thought to be actively proliferating
(Stein et al 1982). A population of migrating B-cells
are also present in the paracortex admixed with T-cells.
The medulla contains B-cells which are terminally differ¬
entiating and differentiated plasma cells (Lennert 1978,
Harris and Bahn 1985). Other B-cell areas such as the
marginal zone although readily identified in the spleen
(Van Krieken and te Velde 1988) are less well demonstrat¬
ed in lymph nodes and tonsils. The use of immunohisto-
chemical technigues allows accurate assessment of the
stage of activation, proliferation and differentiation
of these morphologically defined subsets. The purpose of
this component of the study was therefore to stain a
group of reactive lymph nodes and tonsils with a panel of
MCA against B-cell antigens to define antigen expression
in different B-cell populations. The results would also
be available for subsequent comparison with the pheno-
types of the "equivalent" cells in cases of non-Hodgkin1s
lymphoma.
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3.2 MATERIALS AND METHODS
Tissue:- Reactive lymph nodes and tonsils




Three tonsils and 8 reactive lymph nodes were studied
with the panel of MCA. Reactive lymph nodes were also
used for the titration of individual MCA during the
period of the study. The results from these individual
titrations are not presented but were similar to the
results of the detailed analyses.
A summary of the staining pattern seen in the lymph nodes
and tonsils is shown in Table 3 with more detailed analy¬
sis of individual staining patterns below.
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Table 3 Antigen expression by normal B-cells in tonsilsand
reactive lymph nodes.
Antigen Mantle Germinal Centre Paracortex Plasma Cell
"Pan-B" cell
CD19 +++/DRC +++ + -
CD2 0 +++ +++ + -
CD22 +++ +++ + -
CD4 5R +++ +++ +/++ —
"Restricted-■B" cell
CD5 - ~/+ +++ -
CD9 ++ +/DRC + -
CD10 - - - -
CD38 — +++ + +-
"Activation-•Associated"
CD21 +++ +/DRC + -
CD2 3 +/++ -/DRC "/+ -
CD25 - "/+ +/++ —
CD3 0 - - "/+ -
CD71 +/++ +++ +/++ -
4F2 +/++ +++ +/++ —
MHC Class II
HLA DR +++ +++ ++
HLA DQ +++ +++ ++
HLA DP +++ +++ ++
upan-T" cell
Leu 4 — "/+ +++
+++ = >70%, ++ = 30-70%7 + = 5-30%, 0 = < 5% positive
cells. DRC = Follicular dendritic network positive.
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CD19
CD19 was expressed strongly by mantle zone lymphocytes
and by germinal centre cells (fig 3.1). A weak dendritic
pattern of staining was also present in germinal centres.
Variable numbers of lymphoid cells in the paracortex were
positive. Plasma cells were negative.
CD2 0
CD20 was expressed strongly by germinal centre cells,
mantle zone cells and small numbers of cells in the
paracortex (fig 3.2). Plasma cells were negative.
CD22
CD22 was strongly expressed by mantle zone and germinal
centre B-cells (fig 3.3). A variable number, usually less
than 30%, of paracortical cells were also positive.
Plasma cells were negative.
CD4 5R
CD45R was expressed strongly by germinal centre cells and
mantle zone cells (fig 3.4). Variable numbers, 10-50%, of
paracortical lymphocytes also expressed CD45R. Plasma
cells were negative.
CD5 and CD3
CD5 was expressed strongly by the majority of cells in
the paracortex with small numbers of lymphoid cells in
mantle zones, germinal centres and in the medulla stain¬
ing (fig 3.5). Plasma cells were negative. The staining
pattern was indistinguishable from that of a pan-T-cell
MCA Leu-4 used to show the distribution of T-cells in the
cases studied.
CD9
FMC8 showed strong diffuse dendritic staining in germinal
centres (fig 3.6) but a population of germinal centre B-
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cells showing cytoplasmic positivity could be identified
in areas where the dendritic network was less prominent.
A variable proportion of lymphocytes usually less than
30%, were positive in the mantle zone. Occasional posi¬
tive dendritic processes could also be identified in the
mantle zone. Variable numbers of cells were also positive
in the paracortex and medulla. Vascular endothelial cells
and tonsillar epithelium were also positive.
CD10
Only very few cells in the paracortex and mantle zone
were CD10 positive (fig 3.7). No staining was seen in
germinal centres or by plasma cells.
CD38
CD38 was expressed by a few cells in the mantle zone.
Germinal centre cells were positive (fig 3.8) but a small
population showed very strong expression similar to that
of plasma cells in the medulla.
CD21
CD21 was expressed by mantle zone cells (fig 3.9). There
was diffuse staining of the dendritic network in the
germinal centres which made interpretation of reactivity
of B-cells difficult. In some areas where dendritic
staining was less marked membrane staining of lymphoid
cells could be seen. Small numbers of cells in the para¬
cortex expressed CD21. Plasma cells were negative.
CD2 3
CD23 was expressed by a proportion, 30-70%, of mantle
zone cells. Germinal centre cells were negative except
for a population of dendritic cells in the light zone
(fig 3.10). Only small numbers of cells were positive in
the paracortex. Plasma cells were negative.
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CD2 5
CD25 was expressed by cells in the paracortex. In most
instances mantle zone and germinal centre cells were
negative but in a few cases a population of cells,
mostly large blasts in germinal centres were positive
(fig 3.11). Plasma cells were negative.
CD3 0
CD30 was expressed by occasional cells in the paracortex
and in mantle zones (fig 3.12). The majority of mantle
zone cells, and germinal centre cells and plasma cells
were negative.
CD71
CD71, the transferrin receptor, was strongly expressed by
germinal centre cells and a proportion of mantle zone
cells (fig 3.13). A minority of paracortical lymphocytes
were positive. Plasma cells were negative.
4F2
4F2 was expressed by germinal centre cells and by approx¬
imately 50% of mantle zone cells (fig 3.14). A variable
proportion of paracortical lymphoid cells, 20-50%, also
expressed 4F2. Plasma cells were negative.
HLA DR. DP. and DO
Immunoreactivity for all three antigens were essentially
similar. There was strong staining of germinal centre
cells and mantle zone cells (fig 3.15). In the paracortex
the majority of cells were negative but scattered lympho¬




CD19 expression in a reactive lymph node. Germinal centre
and mantle zone cells are strongly positive.
Figure 3.2
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CD20 expression in a reactive lymph node. Germinal centre
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CD22 expression in a reactive lymph node. There is strong
expression by both mantle zone and germinal centre cells.
Figure 3.4
CD45R expression in a reactive lymph node. Mantle zone,
germinal centre and a proportion of cells in the paracor¬
tex (P) are positive.
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Figure 3.5
CD5 expression in a reactive lymph node. B-cell rich
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CD9 expression in a reactive lymph node. A proportion of
mantle zone (M) and germinal centre cells (G) are posi¬






CD10 expression in a reactive lymph node. A few scattered
cells are positive. Germinal centre and the majority of
mantle cells are negative.







CD38 expression in a reactive lymph node. Germinal centre




CD21 expression by a reactive lymph node. Mantle zone
cells are positive. There is strong dendritic staining in
germinal centres.
CD23 expression in a reactive lymph node. A proportion of
mantle zone cells are positive. Only a sub-population of




CD25 expression in a reactive lymph node. A proportion of
cells in the paracortex (P) are positive with fewer and
more weakly positive cells in the mantle zone (M) and
germinal centre (G).
Figure 3.12




CD71 expression in a reactive lymph node. Germinal centre
cells (G) are positive. A proportion of cells in the
mantle zone (M) and paracortex (P) are also positive.
Figure 3.14
M
4F2 expression in a reactive lymph node. A proportion of




HLA DR expression in a reactive lymph node. Mantle zone
and germinal centre cells are strongly positive. A pro¬
portion of paracortical cells are positive.
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3.4 DISCUSSION
Marginal zones and monocytoid B-cells were not readily
identifiable in the tissue studied and so analyses of
normal B-cell phenotypes was therefore limited to mantle
zone cells, germinal centre cells and plasma cells.
These cells showed phenotypic differences. Mantle zone
cells and germinal centre cells expressed "pan-B" cell
antigens such as CD19, CD20 and CD22 but differed in
expression of "activation" and "differentiation" associ¬
ated antigens including CD21 23, 38, 71, 4F2. Mantle zone
B-cells were positive for CD21, did not express CD38 and
only a proportion expressed CD9, CD23, CD38, CD71 and
4F2. Germinal centre cells expressed CD38, CD71, and 4F2.
A proportion appeared to express CD9 and CD21 but evalua¬
tion of staining was hindered by intense dendritic net¬
work staining presumably of DRCs. Germinal centre B-
cells did not express CD23. Plasma cells showed a unique
phenotype expressing CD38 strongly and not expressing any
of the other antigens studied.
The expression of CD19, CD20, CD22, CD45R and MHC Class
II antigens by the majority of B-cells in follicles is
consistent with the known expression of these antigens
within the B-cell lineage. CD19 is expressed from an
early pre-B-cell stage and is lost only by terminally
differentiating cells (Nadler 1986). CD20 similarly has
broad specificity but is expressed at a slightly later
stage by immature B-cells (Nadler 1986). CD22 has been
reported to be lost by B-cells following activation
(Nadler 1986, Freedman et al 1986,1987) and to be only
weakly expressed or not expressed by germinal centre
cells (Nadler 1986). The strong reactivity of germinal
centre cells in tissue sections seen in this study with
an anti-CD22 MCA has been reported by other workers
(Mason et al 1986, 1987). The differences in reported
expression are a result of using different techniques.
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CD22 is internalised following activation and is subse¬
quently expressed in the cytoplasm (Mason et al 1987).
Cytoplasmic expression by germinal centre cells would be
identified by immunohistology but would not be detected
by the standard flow cytometric techniques used in a
number of laboratories. CD45R, the restricted high molec¬
ular weight form of the leucocyte common, is expressed by
B-cells over much of their development but is lost fol¬
lowing terminal differentiation to plasma cells (Dalchau
and Fabre 1981, Salter et al 1985). It has been classed
as a "pan-B" cell marker in this study although it does
not show complete lineage fidelity being expressed by a
proportion of T cells (Dalchau and Fabre 1981, Salter et
al 1985). MHC Class II antigens are expressed at the
earliest stage of B-cell development and are expressed by
all B-cells except plasma cells. They are not restricted
to the B-lineage being expressed by other lymphoid cells
including antigen presenting cells and activated T-cells
(Guy et al 1986) .
A number of markers associated with B-cell activation and
differentiation in-vitro showed differential staining in
tissue sections. Mantle zone cells were heterogeneous.
The majority expressed CD21 but only a proportion ex¬
pressed CD9, CD23, CD71 and 4F2. They were consistently
CD38 negative. On the other hand germinal centre cells
showed a more consistent phenotype. As expected by acti¬
vated cells CD71 and 4F2 were expressed strongly. CD38
was also expressed by the majority of germinal centre
cells whereas only a minor population appeared to be
expressing CD21. CD23 was not identified on germinal
centre centroblasts or centrocytes. These phenotypes are
similar to those reported in other studies (Hsu and Jaffe
1984, Nadler 1986, McMichael et al 1987).
CD5, CD10, and CD30 which have been previously shown to
be expressed by normal in-vitro activated B-cells or by
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subpopulations of B-cells in normal lymphoid tissue
(Caligaris-Cappio 1982, Bofill et al 1985, Hsu and Jaffe
1984, Waldmann et al 1984, Stein et al 1985) could not be
convincingly demonstrated on the B-cells in the tissues
studied.
CD5 is expressed by fetal primary follicle cells (Bofill
et al 1985) and there appears to be an expansion of CD5
positive B-cells in certain autoimmune conditions
(Taniguchi et al 1987) . Expression of CD5 by mantle zone
cells has been reported (Caligaris-Cappio 1982) but we
have been unable to reproduce these results in this study
although subseguently we have very occasionally seen weak
expression by mantle zone B-cells in reactive lymph
nodes.
CD10 has been reported to be expressed by germinal centre
cells (Hsu and Jaffe 1984, Murray et al 1984) when the
MCA J5 is used. At least two epitopes recognised by
different MCA are present on the CD10 molecule (Clark and
Einfield 1986). Germinal centre cells may not express the
epitope recognised by the MCA (Dako-CALLA) used in this
study. Failure of detection may also have been a sensi¬
tivity problem but this is felt unlikely as titration
experiments showed failure of reactivity when the anti¬
body was used undiluted. Studies of CD10 expression were
therefore carried out at the manufacturers suggested
dilution which showed reactivity with a known positive
lymphoma. A number reactive lymph nodes, tonsils and
cases of NHL studied in this series were also assessed
with the anti-CDIO MCA J5. Non-specific staining of the
majority of cells and tissues in sections was a recurrent
problem with a number of batches of the antibody we used
and the results were felt to be unreliable.
CD30 is expressed by both in-vitro activated B- and T-
cells (Stein et al 1985) but our findings are in agree-
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merit with other reported studies of CD30 expression in
tissue sections of normal lymphoid tissue with only
scattered cells, predominantly in the T-cell rich para¬
cortex being positive (Schwab et al 1982) .
CD25 is expressed by in vitro activated B-cells (Tsudo et
al 1984, Waldmann et al 1984, Jung et al 1984) and ap¬
pears to be important for B-cell growth and differentia¬
tion (Muraguchi et al 1985b, Jung et al 1984) . CD25 does
not appear to be detectable on most B-cells in normal
lymphoid tissue (Miyawaki et al 1984, Sheibani et al
1987b) but our results show that a population of positive
germinal centre cells can be identified. In contrast flow
cytometric analyses of cell suspensions made from tonsils
and lymph nodes shows that >60% of B-cells express this
antigen (Anderson et al 1985) suggesting that a sensitiv¬
ity problem may be the basis of apparent low expression
seen by tissue section immunophenotyping.
In-vitro experiments of B-cell stimulation have shown
constant and seguential changes in antigen expression by
normal B-cells at different stages of activation, transit
through the cell-cycle and with differentiation (Kehrl et
al 1984a,b, Boyd et al 1985a,1986, Gordon and Guy 1988).
As discussed in Chapter 1 Gordon and his colleagues have
put forward the idea that B-cells in GO have three dis¬
tinct levels of activation available to them before entry
into the cell cycle and these may also be asociated with
alterations in antigen expression. Truely quiescent B-
cells which do not express markers of activation are in
a subcompartment termed GOQ. Stimulation of these cells
by mitogens causes progression into the next compartment
termed GOA and induces the expression of CD2 3 (Walker et
al 1986, Gordon et al 1986a, Gordon and Guy 1987) . Cells
in early G1 express 4F2 but loss of IgD and expression of
other activation associated antigens. Following differen¬
tiation there is loss of activation markers, reduction
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in "Pan-B" cell markers such as CD19, CD20 and CD22 with
an increase of CD38 (Boyd et al 1985a, 1986). Equivalent
populations may be demonstrated by immunohistology and
flow cytometric analyses of cell suspensions of B-cells
isolated from lymph nodes and tonsils (Anderson et al
1985, Walker et al 1986, Gordon et al 1986a) . Lymph node
and tonsil derived B-cells show differences in buoyancy
in percoll gradients. High buoyancy B-cells are heteroge¬
neous with respect to activation-antigens (Aman et al
1985) It is possible to identify a population of ultra¬
high density B-cells which appear to be in a true resting
state (Walker et al 1986, Gordon et al 1986a). These
cells do not express markers of activation. Low-buoyancy
cells are CD21 negative and IgD negative. Similar
phenotypes are expressed by mantle zone cells and germi¬
nal centre cells respectively in tissue sections.
Secondary follicles are complicated structures comprising
mantle zone B-cells surrounding a germinal centre with
centroblasts, centrocytes and DRCs (Stein et al 1982).
Cytoplasmic processes from DRCs extend into the mantle
zones (Stein et al 1982). Mantle zone cells are part of
the recirculating B-cell population (Gray et al 1982) and
when activated migrate into the germinal centres where
they are transformed into proliferating centroblasts
(Stein et al 1982). Centroblasts subsequently differenti¬
ate into the second germinal centre B-cell population,
the centrocyte. Thus in the tissue sections the lymphoid
secondary follicle allows a putative linear pathway of
activation and differentiation from mantle zone cell to
centroblast and centrocyte to be compared with in-vitro
recognised changes.
Mantle zone cells express IgD, IgM and CD21 and have been
believed to be resting cells (Stein et al 1980, 1982,
Stashenko et al 1981, Hsu and Jaffe 1984). The results
presented here show that a significant proportion of
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mantle zone cells are expressing activation markers
including CD23, CD71 and 4F2 suggesting that they are
actively cycling or at arrest points in the cell cycle.
Cytoplasmic processes extending from germinal centre DRCs
may be involved in the activation of antigen specific B-
cells by presenting antigen to cells in the mantle. These
activated mantle zone cells may migrate into the germinal
centres and undergo further morphological and phenotypic
changes to be recognised as centroblasts. Centroblasts
are proliferating cells and their phenotype reflects
their stage of activation. They have lost IgD and proba¬
bly also CD21. Some centroblasts appear to express CD21
consistent with transient increase of expression follow¬
ing activation. CD71 and 4F2 are strongly expressed
however other markers associated with B-cell activation
and proliferation such as CD23 and CD25 are not detected
or are seen on only a minor population of germinal centre
cells by immunohistology. CD23 is shed by proliferating
B-cells in-vitro (Gordon and Guy 1987) and a similar
phenomenon may be occurring in germinal centres with
centroblasts shedding the antigen which is then absorbed
by a subpopulation of DRCs from where it may function as
a B-cell growth factor. Centroblasts differentiate into
the centrocytes, which are believed to be a non-prolifer¬
ating cells. Both germinal centre cell types express CD71
and 4F2. Expression of both these antigens is enhanced by
activation of B-cells but expression does not appear to
be tightly associated with proliferation (Hemler and
Strominger 1982, Pileri et al 1987). Centroblasts and
centrocytes express CD38 with a minority of germinal
centre cells, probably plasma cells, showing strong
expression. In-vitro, CD38 expression is usually associ¬
ated with differentiation to immunoglobulin secreting
cells (Boyd et al 1985a). The ultimate fate of germinal
centre derived cells is not clearly known but as they are
the prime source of memory cells and contribute to the
recirculating B-cell memory pool (Klaus and Kunkl 1981)
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it is likely that centrocytes migrate and become morpho¬
logically identifiable lymphocytes which recirculate in
the blood to lymphoid and other tissues. As recirculating
cells do not express CD38 it would appear that CD38
expression is only a transient phenomenon in the develop¬
ment of B-cells whose expansion is via the germinal
centre.
The medulla is rich in plasma cells and the phenotypes of
these cells is similar to B-cells which have been stimu¬
lated in-vitro to Ig secreting cells in that they ex¬
press CD38 strongly and have lost Mpan-B"-cell markers,
MHC Class II and markers of activation.
In conclusion detailed analyses of antigen expression in
reactive lymph nodes and tonsils show differences between
the major identifiable groups of B-cells :- mantle zone
cells, germinal centre cells and plasma cells. Mantle
zone cells are phenotypically heterogeneous containing a
population of cells expressing the activation associated
antigens CD23, CD71 and 4F2. Germinal centre cells show
increased expression of activation associated antigens
but have lost CD23 and CD21. Plasma cells have lost all
B-cell specific markers and markers of activation but
express CD38 strongly. These phenotypic differences are
similar to those demonstrated in vitro following mitogen
induced B-cell activation, proliferation and differentia¬
tion.
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CHAPTER 4; ACTIVATION AND DIFFERENTIATION ANTIGEN
EXPRESSION BY B CELL NON-HODGKIN'S LYMPHOMA
4.1 INTRODUCTION
Non-Hodgkin•s lymphomas are believed to result from
proliferation and accumulation of lymphoid cells at
different stages of differentiation. Currently used
classifications of NHL, such as the Kiel classification
(Lennert 1978, Stansfeld et al 1988), are based upon the
belief that the morphology and immunophenotypes of NHL
correspond to normal cells at varying stages of differen¬
tiation and activation ranging from lymphoid precursor
cells to terminally differentiated T or B-cells e.g.
lymphoblastic NHL - immature pre B/thymic T cells; cen-
troblastic/centrocytic NHL - follicle centre cells;
immunoblastic NHL and plasmacytoma - terminally differen¬
tiated cells. Previous studies have shown some correla¬
tion between antigen expression and certain morphological
features of B-cell NHL (Habeshaw et al 1983, Anderson et
al 1984, Stein et al 1984, Nash 1986) but only a rela¬
tively limited number of anti-B-cell MCA were used. It
is possible differential expression of activation and
differentiation antigens by NHL may assist pathological
diagnosis and allow more accurate definition of subtypes
of NHL within morphologically similar groups. The second
part of this study was undertaken to investigate these
possibilities.
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4.2 MATERIALS AND METHODS
4.2.1 Cases:- 148 cases of B-cell NHL




A total of 148 B-cell NHL were studied. The numbers in
each histological group and anatomical site of biopsy are
shown in Table 4.1. Detailed results of antigen expres¬
sion of cases in each histological group are given in
Tables 4.2 - 4.11 (pages 78-87). Results for lymphocytic,
centrocytic, follicular centroblastic/centrocytic, dif¬
fuse centroblastic/ centrocytic, centroblastic, immuno-
blastic and plasmacytic/blastic are summarised and pre¬
sented as histograms in Histograms 4.1 -4.7 (pages 88-
94) .
4.3.1 Lymphocytic lymphoma
Eighteen cases of lymphocytic lymphoma (figure 4.1) were
studied (Table 4.2, Histogram 4.1) derived from lymph
nodes (16), spleen (1) and breast (1). All cases ex¬
pressed monotypic immunoglobulin: 16 cases expressed
kappa and 2 cases expressed lambda; 16 expressed IgM
with co-expression of IgD in 7; 1 case expressed IgG
alone and 1 monotypic kappa light chain without heavy
chains. The pan-B-cell markers CD19, CD22 and CD45R were
strongly expressed by all cases. The CD20 marker B1
showed variable and often weak staining between and
within cases. All cases tested expressed the CD5
antigen (figure 4.2). CD9 was expressed on a proportion
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of cells in 11 cases. Staining was strongest outwith
proliferation centres. There was no staining for CD10 or
CD38. CD21 (C3d receptor) was expressed by the majority
of cells in all cases (figure 4.3), including one case
(573) which did not express slgD, although lymphomas
which expressed IgMD tended to show stronger reactivity
than those expressing IgM alone. CD23 was expressed by
the majority of cells in 7 cases (figure 4.4) and by a
minority in 1. CD25, the interleukin 2 receptor, was
expressed weakly by the majority of cells in 6 cases.
There was no expression of CD30 in the 3 cases tested.
CD71 and 4F2 were variably expressed: in some cases both
antigens were expressed by the majority of cells whilst
in others only a proportion of cells stained (figure
4.5). Expression of both antigens was enhanced in pro¬
liferation centres (figure 4.6) . All cases expressed
HLA DR and DP antigens with absent or low DQ expression
in a proportion of cases. MHC Class II expression was
enhanced in proliferation centres.
4.3.2 Lvmphoplasmacvtic lymphoma (immunocvtoma)
Two cases (figure 4.7) - one lymph node and one soft
tissue mass - were studied (Table 4.3). The nodal case
was IgM positive with a phenotype similar to that of
small lymphocytic lymphomas expressing CD22, CD45R and
MHC Class II antigens but not CD5. The other case was
IgGK positive and showed loss of pan-B-cell antigens with
decreased MHC class II antigen expression and absence of
CD5. CD38 was not expressed by either tumour.
4.3.3 Prolvmphocvtic lymphoma
Four cases (figure 4.8) were available for study (Table
4.4), these being from spleen (2), lymph node (1) and
orbit (1) . All cases expressed IgM together with IgD or
IgG in two cases. All cases expressed pan B cell anti¬
gens although expression of CD20 was weak in one. Two
cases expressed CD5 strongly, one weakly and one was
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negative. None expressed CD9, CD10 ( 3 cases) or CD38.
CD21 was expressed strongly by one case and by a minority
of cells in the other studied. Neither of the 2 cases
studied expressed CD23 and only 1/4 cases expressed CD25
weakly. The one case tested did not express CD30. Both
CD71 and 4F2 were strongly expressed by all four cases.
DR and DP were strongly expressed by all 4 cases, but DQ
was expressed by only a proportion of cells in 3 cases.
4.3.4 Hairy cell leukaemia
All 3 cases of hairy cell leukaemia (figure 4.9) studied
were resected spleens (Table 4.5). All were kappa posi¬
tive with one IgMA, one IgMD and one IgG positive. They
expressed the pan-B antigens CD19, CD20, CD22 and CD45R
but not CD5. One was CD9 positive. Two expressed CD10
weakly in the cytoplasm. None of the cases expressed
CD38 but one was positive for CD23. All expressed the
CD25 antigen (figure 4.10). Neither of the two cases
tested expressed CD30. CD71 and 4F2 expression were weak
or absent in 2/3 cases. DR and DP were strongly ex¬
pressed by all 3 cases whereas only two showed DQ expres¬
sion.
4.3.5 Centrocvtic lymphoma
12 cases of centrocytic lymphoma (figure 4.11) were
studied from lymph nodes (8), tonsil (1) , spleen (2) and
small intestine (1) (Table 4.6, Histogram 4.2). All
expressed monotypic IgM, and 5/10 tested coexpressed IgD.
5 cases expressed lambda and 7 kappa light chains. All
cases tested stained strongly for pan-B-cell antigens and
CD5 (figure 4.12). CD9 was expressed by a proportion of
cells in 7 cases but was expressed strongly by only 3
cases. None expressed CD10 and only a proportion of
cells in 2 cases expressed CD38. All 5 cases tested were
CD21 positive and CD23 negative (figure 4.13). 2 cases
expressed CD25. In one the majority of cells stained
weakly whereas in the other only a minority of cells were
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staining. CD30 was not expressed by either of the two
cases tested. Numbers of cell staining with 4F2 and
CD71 varied between cases. In most cases staining was
weak or restricted to a minority of cells. Although DR
and DP were expressed strongly in all cases DQ was often
absent or weak.
4.3.6 Follicular centroblastic/centrocvtic lymphomas
A total of 39 cases (figure 4.14) were studied (Table
4.7, Histogram 4.3) from lymph nodes (36), spleen (1),
thyroid (1) and breast (1). Twenty three cases expressed
kappa, 14 lambda light chains and in 2 cases immunoglobu¬
lin staining was negative or equivocal. Thirty cases
expressed IgM with coexpression of IgD (4), IgG (1) and
IgA (1): 6 cases expressed IgG alone and one lacked
heavy chains but expressed lambda light chain. The
majority of cases expressed pan-B-cell antigens strongly
and were CD5 negative. CD10 (24/36) (figure 4.15), and
CD38 (13/38) were variably expressed. CD9, CD21 and CD23
were also variably expressed. Assessment of their ex¬
pression was complicated by strong DRC staining (figure
4.16) but in a number of cases the dendritic network was
less intense and definite staining of lymphocytes could
be demonstrated (figure 4.17). Four cases (723, 732, 760,
and 855) showed strong CD21 expression by the neoplastic
follicle cells. These cases did not show CD23 staining
and showed strong CD9 expression. CD25 was expressed by
neoplastic cells in only 2/36 cases. None of the cases
tested expressed CD30. 4F2 and CD71 showed similar but
variable expression between cases although in some cases
there was differential expression e.g. strong expression
of 4F2 and weak CD71 or vice versa. The majority of the
cases expressed DR, DP and DQ, although DQ expression
was often reduced or absent.
It was not possible to correlate variation in cellular
content of follicles (i.e. proportion of centroblasts to
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centrocytes) with any particular phenotype. Three cases
(449, 760 and 879) contained a predominant proportion of
centroblasts. All three expressed monotypic IgM kappa and
CD9 strongly but showed variable expression of CD10 and
CD21. All cases were CD23 negative and expressed CD71 and
4F2 strongly.
4.3.7 Diffuse centroblastic/centrocvtic lymphoma
Thirteen cases of diffuse centroblastic/centrocytic
lymphoma (figure 4.18) were studied (Table 4.8, Histogram
4.4) derived from lymph nodes (9; two of which had ex-
tranodal spread), small intestine (2) testis (1) and
omentum (1). Eight cases expressed kappa and three cases
lambda. The testicular tumour and an intestinal lesion
did not express light chains. Ten cases expressed IgM
together with IgD in two instances. Three cases
expressed IgG, one without light chain. The majority of
cases expressed CD19, CD22 and CD45R whereas in a few
cases CD20 expression was weak or absent. None of the
cases were CD5 or CD38 positive. Two cases expressed
CD9 and a further two CD10. CD21 was expressed by the
majority of lymphoid cells in only 3 cases. DRCs in 5/6
cases stained for CD21. CD23 was expressed by the
majority of cells in 3/7 cases but CD25 staining was
observed in only two cases. Neither of the 2 cases
tested expressed CD30. 4F2 was expressed strongly in all
cases whereas CD71 staining was seen on only a minority
of cells in 4 cases the remainder staining strongly. The
MHC class II antigens DR, DP and DQ were strongly
expressed in all cases.
4.3.8 Centroblastic lymphoma
Thirty four cases of centroblastic lymphoma (figure 4.19)
from lymph nodes (24) , stomach (2) , testis (2) , omentum
(1), mediastinum (1), tonsil (1), retroperitoneum (1)
breast (1) and scalp (1) were studied (Table 4.9, Histo-
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gram 4.5). Seventeen cases expressed kappa, 9 lambda
light chains and 1 case gave equivocal results. 16
cases expressed IgM, one with IgD, 9 IgG and 3 IgA; 3
cases expressed heavy chains without light chains. 4
cases did not express immunoglobulin. Whilst the major¬
ity of cases expressed pan-B-cell antigens strongly, a
few cases showed loss of one or more of these antigens
(figure 4.20). CD5 expression was seen in only one case.
There was variable expression of CD9, CD10 and CD38
antigens. No relationship was observed between the
expression of these antigens with all possible permuta¬
tions being seen within the series. Twelve of 19 cases
tested expressed CD21 although the intensity of staining
was often weak in comparison with other lymphomas. In
only one of 20 cases was there more than a very minor
population of cells or DRCs expressing CD23. CD25 and
CD30 were expressed by a minority of cases only whereas
4F2 and CD71 were strongly expressed by the majority
(figure 4.21). DR, DP and DQ were expressed strongly by
most of cases, although a few showed loss of one or more
antigens.
Five cases (no.s 676, 785, 913, 923, and 935) contained
a large proportion of multilobated cells. Despite their
morphological differences from the remainder of the group
they did not show distinct phenotypes. These cases ex¬
pressed pan-B-cell antigens and CD38; in 2 cases tested
these cells were CD21 positive and CD23 negative. None
expressed CD9. Two of these cases (913 and 923) expressed
CD3 0.
4.3.9 Immunoblastic lymphoma
Fourteen cases of immunoblastic lymphoma (figure 4.22)
were studied (Table 4.10, Histogram 4.6). In this group
we included two cases of polymorphic immunocytoma (592
and 653) containing an admixture of plasma cells and
plasmablasts with a predominance of immunoblasts. Ten
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cases were lymph nodes and 4 extranodal (1 retroperitone-
um, 1 chest wall mass, 1 knee and 1 spleen). Eleven
cases expressed kappa and 3 lambda light chains. Eight
expressed IgM together with IgD and with IgA in another.
Five cases expressed IgA alone and in 1 case IgA and IgG
were coexpressed. There was variable expression of
pan-B-cell antigens. CD22 and CD45R were most commonly
expressed, however, these and other pan-B-cell antigens
were often lost or only expressed by a minority of tumour
cells (figure 4.23). CD5 and CD9 were not expressed.
CD10 staining was observed in only one case (299). This
tumour, although showing a vast majority of immunoblasts,
in addition contained a population of large centrocytes
and centroblasts suggesting derivation from a diffuse
centroblastic/centrocytic lymphoma. Almost half of the
cases expressed CD38. This was strongest in the cases of
polymorphic immunocytoma and in cases showing plasmablas-
tic differentiation. However, two cases showing plasma-
cytoid differentiation morphologically (nos 478 and 616)
did not express CD38. CD21 was expressed by a minority
of cases and CD23 was expressed weakly by the majority of
cells in only one case tested. Staining for CD25 was
inconsistent, whereas both 4F2 and CD71 were strongly
expressed by all cases (figure 4.24). In one case the
majority of cells expressed CD30 and in two others a
minority of large blast cells were positive. The MHC
class II antigens DR, DP and DQ were strongly expressed
in all cases.
4.3.10 Plasmacytic/Plasmablastic lymphoma (Plasmacytoma)
Seven cases (figure 4.25) were studied (Table 4.11) from
lymph nodes (4) and extranodal tissues ( 1 sacral tumour,
1 epidural tumour and 1 testicular tumour). These cases
included tumours which were composed either wholly by
plasma cells or cases in which the majority of cells
appeared plasmablastic that is showed cytological appear¬
ances of plasma cells but with vesicular nuclei with one
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or more prominent nucleoli. Both case nos 856 and 901
were recurrences from previously diagnosed myelomas, in
which the predominant cell types were now plasmablasts.
Six cases expressed kappa and 1 lambda light chain. All
7 expressed IgG, one in association with IgA. All of the
cases tested had lost CD19 and CD20 whilst CD22 was
expressed by a proportion of cells in 2 cases only
(figure 4.26). CD45R expression was observed by a major¬
ity of cells in 4 cases. All cases expressed CD38 (figure
4.27) and 4/7 expressed CD9. None of the cases tested
expressed CD5, CD10, CD21, CD23 or CD30 and only one
showed weak expression of CD25. The MHC class II anti¬
gens were lost by 6/7 cases (figure 4.28) although one
did contain a minor population of class II positive
plasma cells.
4.3.11 Lymphoblastic lymphomas
Only 2 cases morphologically diagnosed as lymphoblastic
lymphomas (figure 4.29) were available for study (Table
4.12). One was an epidural tumour and the other a spleen.
Both were terminal deoxynucleotidyl transferase positive.
One case did not express immunoglobulin and the other
expressed monotypic IgM lambda. The immunoglobulin
negative case expressed CD19, CD22, CD9 and CD10 (figure
4.30) but none of the other pan-B-cell or B-cell differ¬
entiation associated antigens including MHC class II.
The other case expressed all four pan-B-cell antigens,
CD9, CD10, CD38 and MHC Class II antigens but did not
express CD21 or CD23. Both cases were strongly 4F2 and
CD71 positive.
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LN=lymphnode,SMINTs allintestin ,NDtdone,3>70%20-70 ,15-3
0=<5%tumourcellsstaining.
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Lymphocytic lymphoma (LG no. 961) comprising a diffuse
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Lymphocytic lymphoma (LG no. 961). There is strong ex¬
pression of CD21 by tumour cells and residual DRCs.
Figure 4.4
Lymphocytic lymphoma (LG no.961). There is strong expres¬
sion of CD23 by the majority of cells.
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Lymphocytic lymphoma (LG no. 807 ) . Only a minor
population of cells are expressing the activation associ¬
ated antigen 4F2.
Figure 4.6
Lymphocytic lymphoma (LG no.597). Expression of CD71 is
enhanced in proliferation centres (PC).
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Lymphoplasmacytic lymphoma (LG no. 717). The tumour
comprises a diffuse infiltrate of small lymphoid cells
with clumped nuclear chromatin and moderate amounts of
basophilic cytoplasm.
Figure 4.8
Prolymphocytic lymphoma (LG no. 297). The predominant
cell is a small to medium sized lymphoid cell with one or
more small nucleoli.
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Hairy cell leukaemia (LG no. 425). The splenic red pulp
contains a diffuse infiltrate of small to medium sized
cells with clumped nuclear chromatin and moderate amounts
of pale cytoplasm.
Figure 4.10
Hairy cell leukaemia (LG no. 425). There is predominantly
cytoplasmic expression of CD25.
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Figure 4.11
Centrocytic lymphoma (LG no. 960). There is a diffuse
infiltrate of small to medium sized cells with irregular
nuclei and clumped nuclear chromatin.
Figure 4.12
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Centrocytic lymphoma (LG no. 960). There is strong ex¬




Centrocytic lymphoma (LG no. 960). The tumour cells do
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Follicular Centroblastic/centrocytic lymphoma (LG no.
866). The normal lymph node architecture is replaced by a




Follicular centroblastic/centrocytic lymphoma (LG no.
836). the neoplastic follicles are expressing CD10
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Follicular centroblastic/centrocytic lymphoma (LG no.
957). There is strong dendritic expression of CD21 in the
neoplastic follicles.
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Follicular centroblastic/centrocytic lymphoma (LG
no.866). There is dendritic network staining in the
follicle but expression of CD9 by lymphoid cells can also
be seen.
Diffuse centroblastic/centrocytic lymphoma (LG no. 85) .
The normal lymph node architecture is replaced by a




Centroblastic lymphoma (LG no. 563). The tumour consists
of a diffuse infiltrate of large cells with vesicular
nuclei and multiple peripheral nucleoli.
Figure 4.20
Centroblastic lymphoma (LG no.1050). The neoplastic cells




Centroblastic lymphoma (LG no. 745). THe majority of
cells are expressing 4F2 strongly.
Figure 4.22
Immunoblastic lymphoma (LG no. 406). The predominant cell




Immunoblastic lymphoma (LG no. 701). A proportion of
cells only are expressing CD22.
Figure 4.24
Immunoblastic lymphoma (LG no. 406). CD71 is expressed
strongly by the majority of cells.
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Figure 4.25
Plasmacytoma (LG no. 49). The tumour consists of a dif¬
fuse infiltrate of plasma cells.
Figure 4.26
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Plasmacytoma (LG no. 747). Only macrophages and dendritic




Lymphoblastic lymphoma (LG no. 503). The tumour consists
of a diffuse infiltrate of medium sized blasts. There is
a prominent starry-sky appearance.
Figure 4.30




This part of the study reports the phenotypic expression
of a series of B-cell NHL using a panel of MCA against
B-cell differentiation and activation antigens. There
was marked phenotypic heterogeneity both within and
between the major morphological subgroups recognised by
the Kiel classification. This heterogeneity was so ex¬
treme that a unigue phenotype for one morphological group
was not defined although common patterns of expression of
certain antigens was apparent.
No single marker in the panel reacted with all cases
tested. The B-cell histogenesis of the cases was con¬
firmed by demonstrating either monotypic immunoglobulin
light chain or expression of one or more pan-B-cell
restricted antigens. A few cases, predominately within
the centroblastic and lymphoblastic groups failed to
express immunoglobulin. In these cases at least one or
more pan-B-cell antigen could be demonstrated. Similar
findings have been reported by others (Anderson et al
1984, Stein et al 1984, Horning et al 1984, Borowitz et
al 1985). The finding that B1 which recognises CD20
failed to stain or showed weak reactivity in a number of
our cases confirms previous observations of poor reactiv¬
ity of this antibody in tissue sections (Mason et al
1986, Horning et al 1984, Freedman et al 1985). This
may be a technical artifact as strong reactivity is seen
when cell suspensions are employed (Anderson et al 1984).
Earlier reports have shown that 'null1 cell tumours
expressing neither surface immunoglobulin or sheep ery¬
throcyte receptors constitute approximately 5% of NHL
(Lukes et al 1978, Pinkus and Said 1978). Many such
cases have been shown to be of B or T-cell lineage by
immunophenotyping (Knowles et al 1985, Cleary et al
1985). Using a panel of anti-B-cell, anti-T-cell and
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anti-macrophage MCA every case of approximately 250 NHL
seen in the Pathology Department of Edinburgh University
over the period of the study have been assigned to
either B-cell, T-cell or macrophage/histiocyte lineage
suggesting that "null"-cell tumours are rarely seen
(unpublished observation).
Four of the MCA used in the panel are known to recognise
antigens (CD5, CD9, CD10 and CD38) expressed at variable
or multiple stages of B-cell differentiation. These are
potentially useful for defining subgroups of B-cell NHL
immunologically and for comparison with normal cellular
counterparts. CD5, an antigen expressed predominantly by
T cells (Royston et al 1980) is expressed by a proportion
of mantle zone B cells (Caligaris-Cappio 1982) and fetal
primary B cell follicle cells (Bofill et al 1985). In
this series CD5 expression was restricted predominantly
to lymphocytic and centrocytic lymphomas confirming the
findings of others (Swerdlow et al 1983 1984, Cossman et
al 1984b, Anderson et al 1984). A few cases of follicular
centroblastic/centrocytic, centroblastic and prolympho¬
cyte groups were also CD5 positive. A small number of
CD5 positive follicular lymphomas have previously been
reported (Anderson et al 1984, Borowitz et al 1985). The
finding that prolymphocytic lymphoma was frequently CD5
positive agrees with Stein et al (1984) but contrasts
with Gobbi et al (1983) who found 12 cases of prolympho¬
cytic leukaemia to be CD5 negative. The latter studies
employed a MCA RFA-2 on suspensions of peripheral blood
cells and may reflect differences in antigen expression
between neoplastic cells in tissues and blood. Alterna¬
tively histologically recognised prolymphocytic lymphoma
may be a different disease entity from prolymphocytic
leukaemia. The case of prolymphocytic lymphoma from the
orbit could possibly be a high grade MALToma (Isaacson et
al 1988) .
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CD9 which is expressed by a proportion of germinal centre
and mantle zone cells (Hsu and Jaffe 1984, Murray et al
1984) in reactive lymph nodes was variably expressed in
all groups studied except immunoblastic lymphomas which
were all negative. It was therefore not of value for
subtyping B-NHL whereas others using a different CD9 MCA
(BA-2) have suggested this antigen may be selectively
expressed by mantle zone lymphomas (Cossman et al 1984a).
In lymphocytic lymphomas expression of CD9 was either
absent or reduced in proliferation centres, suggesting
this antigen reflects a stage of activation rather than
differentiation.
CD10 expression by lymphoblastic lymphomas is well recog¬
nised (Ritz et al 1981), and expression by reactive
follicle centre cells has been described (HSu and Jaffe
1984, Murray et al 1984). The results presented here
confirm the expression of this antigen by at least a
proportion of neoplastic follicle centre cell tumours
(Anderson et al 1984, Stein et al 1984, Swerdlow et al
1985, Williamson et al 1986). CD10 positivity has been
shown to correlate with more aggressive myeloma (Durie
and Grogan 1985). This raises the possibility that the
variable expression of CD10 in cases of centroblastic and
immunoblastic lymphoma seen in our study represents
similar aggressive subgroups. None of the
plasmablastic/plasmacytomas in this study expressed CD10.
In normal lymphoid tissue CD38 is a marker of plasma
cells (Bhan et al 1981, Anderson et al 1984) and is
expressed by follicle centre cells but not mantle zone
cells (Anderson et al 1984, Gobbi et al 1983, Hsu and
Jaffe 1984, Murray et al 1984). CD38 showed correspond¬
ing expression in this series being expressed by a pro¬
portion of follicular lymphomas and plasmacytomas as
previously documented (Anderson et al 1984, Gobbi et al
1983). Similarly reactivity with B cell lymphoblastic
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lymphomas has been described (Gobbi et al 1983). Al¬
though CD38 positivity frequently correlated with plasma
cell differentiation histologically, in 2 cases of lym-
phoplasmacytoid lymphomas (immunocytoma) and in two cases
of immunoblastic lymphoma with large numbers of plasma-
blasts this antigen was not expressed. Unlike other
plasma cell tumours the cases of lymphoplasmacytoid
lymphoma expressed MHC class II antigens and in 1 case
pan-B cell antigens. In contrast to lymphocytic lympho¬
mas they were CD5 negative. Other workers have also
recognised the distinct phenotypic characteristics of
this group of NHL and have postulated that they may
represent proliferations of a subpopulation of normal
lymphoid cells (Stein et al 1984, Harris and Bhan 1985).
The panel of MCA included some which recognise 'activa¬
tion associated' antigens. CD21, the C3d receptor (Iida
et al 1983, Tedder et al 1984) is present on resting B-
cells but is lost following in vitro activation (Stashen-
ko et al 1981, Dorken et al 1985); others, such as CD23,
CD25, CD30, CD71 and 4F2, are absent from resting cells
but can be induced by mitogens (Waldmann et al 1984,
Stein et al 1985, Haynes et al 1981, Thorley-Lawson et al
1985, Walker et al 1986, Walker and Gordon 1987). Ex¬
pression of one of these antigens, CD71, has been shown
to be correlated with histological grade and clinical
outcome of NHL (Habeshaw et al 1983, Pileri et al 1984).
In nearly all cases tested at least a proportion of
neoplastic cells were activated as shown by expression of
CD23, CD71 or 4F2. Many cases also expressed CD21, an
antigen lost rapidly following activation of splenic B
cells by anti-Ig (Boyd et al 1985a,1986, Dorkan et al
1985) . Other workers have reported similar heterogeneity
in expression of CD21 (Horning et al 1984, Borowitz et al
1985) and it is possible that the expression of this
antigen by activated cells represents abnormal regulation
by the neoplastic cells. Continual stimulation of the
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cell via this antigen may contribute to uncontrolled
proliferation.
CD23 is expressed within 3 hours following activation of
resting B-cells, before cells enter the cell cycle
(Thorley-Lawson et al 1985, Walker et al 1986). In
reactive lymph nodes and tonsil it is expressed at varia¬
ble intensity by mantle zone lymphocytes and by a propor¬
tion of DRCs (Mason et al 1986) but not by germinal
centre centrocytes or centroblasts. CD23 was maximally
expressed by the low grade lymphomas (lymphocytic lympho¬
mas) and infreguently expressed by high grade (centro-
blastic or immunoblastic) tumours. Similar observations
have been made by others (Stein et al 1984) and it is
possible that CD23 is expressed only transiently during
B-cell activation and is lost after a certain stage of
committed differentiation. Failure of germinal centre
cells to express CD23 would support this idea. The
observation that lymphocytic lymphomas were CD23 posi¬
tive whereas centrocytic lymphomas were negative is
consistent with previous reports (Stein et al 1984) and
may be a useful means of differentiating these subtypes
although CD23 positive centrocytic lymphomas have been
reported (Williamson et al 1986).
CD25 was initially shown to be expressed by activated T-
cells (Uchiyama et al 1981). Recent work however has
also demonstrated its expression by activated normal B-
cells (Waldmann et al 1984, Tsudo et al 1984) and by
hairy cell leukaemia (Korsmeyer et al 1983). The findings
in this study are that CD25 is also variably expressed in
most histological groups of B-NHL although there was no
correlation with histological grade. Chronic lymphocytic
leukaemia cells proliferate and differentiate in response
to IL2 (Lantz et al 1985, Hivroz et al 1986) and it is
possible the growth of at least some B-cell lymphomas is
regulated through abnormal receptor expression and stimu-
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lation by IL2.
CD30 (Kil) was initially described as reacting selective¬
ly with Reed-Sternberg cells in Hodgkin•s disease and
with a small population of large cells in reactive lymph
nodes (Schwab et al 1982). Recent work has shown that
CD30 can be induced in B-cells by mitogens and infection
with Epstein-Barr virus (Stein et al 1985). CD30 was
present in only a small number of high grade lymphomas
(centroblastic or immunoblastic) in this series consist¬
ent with the findings of others (Stein et al 1985).
The activation-associated antigens 4F2 and CD71 were most
strongly expressed by high grade lymphomas and less often
and more weakly by low grade lymphocytic and follicular
lymphomas. Increased expression of transferrin receptor
in high grade lymphomas has been shown previously (Habe-
shaw et al 1983, Pileri et al 1984), but the results
presented here demonstrate more heterogeneity in low
grade lymphomas than has been previously described.
The expression of MHC Class II antigens extends and
confirms results previously published (Krajewski et al
1985, Guy et al 1986, Smith et al 1987) with coordinate
and non-coordinate expression of DR, DP and DQ being
evident in many histological groups. The increased
expression of Class II antigens in the proliferation
centres of lymphocytic lymphomas and in-vitro following
entry of B-cells into the cell cycle (Kehrl et al 1985)
suggests that these antigens are involved in B-cell
activation. However the finding that their expression is
decreased or absent in tumours showing plasma-cell dif¬
ferentiation and that centrocytic lymphomas and some
centroblastic lymphomas tend to show low DQ expression
suggests that MHC class II antigens may also be differen¬
tiation related.
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Many of the histological groups of B-NHL recognised by
the Kiel Classification system show cytomorphological and
phenotypic similarities to normal B-cells. It is gener¬
ally accepted that neoplastic cells reflect normal B-
cells frozen at various stages of maturation. However,
the phenotypic heterogeneity observed within the various
histological categories shows that direct comparison with
morphologically similar normal counterparts cannot be
made in all cases. There are a number of possible
reasons for this. Phenotypic heterogeneity may represent
multiple stages of activation/differentiation arrest
along a linear pathway which are only transient in vivo
and therefore seldom seen. Alternatively it may indicate
maturation arrest of morphologically similar cells which
are already committed to different non-linear differenti¬
ation pathways. The phenotypic diversity, especially
marked in high grade NHL, is likely in part to represent
abnormal expression of differentiation and activation
antigens secondary to loss of genomic regulation in
neoplastic cells. As many of these activation and dif¬
ferentiation antigens appear to have a functional role in
control of B-cell differentiation and proliferation
abnormal expression may be intimately involved in lympho-
magenesis.
In conclusion detailed analysis of B-cell NHL using a
panel of MCA against B-cell activation and differentia¬
tion antigens shows marked phenotypic heterogeneity both
between and within morphological groups. The B-cell
histogenesis in some cases can only be confirmed by using
a panel of immunoglobulin and pan B-cell markers. Pan-B-
cell (CD19, CD20, CD22, CD45R) and 'restricted' B-cell
antigens (CD5, CD9, CD10, CD38) were in general unhelpful
markers of morphological groups although CD5 (lymphocytic
and centrocytic NHL) and CD38 (plasma cell tumours) were
expressed strongly by some groups. Activation antigens
were expressed by cases in all histologic groups but 4F2
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and CD71 (transferrin receptor) were more often and more
strongly expressed by high grade lymphomas. They may
therefore be of prognostic significance. Other activa¬
tion antigens like CD23 and CD25 did not appear to be
more frequently associated with high grade tumours but
CD23 may be useful in the discrimination between centro-
cytic and lymphocytic lymphoma.
Detailed phenotyping by a large panel of MCA such as used
in this study may be of value for elucidating biological¬
ly important characteristics and cellular abnormalities
in NHL. However for routine diagnostic purposes such
extensive typing of NHL is probably not of practical use
at present. As an adjunct to routine histological exami¬
nation a limited panel of MCA against leucocyte antigens
CD3, CD5, CD19 or CD22, CD45, IgM, kappa and lambda would
be sufficient for frozen section immunohistochemistry for
diagnostic purposes. This panel allows diagnosis of most
cases of NHL. The use of additional MCA's against other
leucocyte antigens (CD1, CD4, CD8, CD23, CD25) would need
to be undertaken only in selected cases where the initial
screen gives equivocal results.
Detailed analysis of immunophenotypes therefore does not
appear to be of much value to the histopathologist for
diagnostic purposes. The variation of expression of many
of the antigens studied, a number of which have been
shown to be involved in B-cell activation and prolifera¬
tion or to function as receptors for growth factors,
raises the possibility that there expression may be
associated with progression of the disease and clinical
prognosis. The next component of the study was to inves¬
tigate this possibility.
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CHAPTER 5 PROGNOSTIC SIGNIFICANCE OF B CELL
NON-HODGKINS LYMPHOMA IMMUNOPHENOTYPE
5.1 INTRODUCTION
Classifications of NHL such as the Kiel Classification
(Lennert 1978, Stansfeld 1988) and Working Formulation
(Rosenberg 1982) identify different morphologic catego¬
ries which may be separated into major prognostic group¬
ings. Immunophenotyping aids categorisation of NHL into T
and B-cell groups. As demonstrated in Chapter 4 detailed
analysis of the expression of activation and differenti¬
ation antigens using a large panel of antibodies shows
phenotypic heterogeneity within morphologically similar
groups. Previous studies of antigen expression have
shown a correlation with survival in NHL although in
these studies only a limited number of markers have been
used. CD71 (transferrin receptor) and 4F2 expression is
associated with poor survival (Habeshaw et al 1983,
Pileri et al 1984, Holte et al 1987), whereas MT2 expres¬
sion by colorectal lymphomas is associated with a better
prognosis (Shepard et al 1988). CD23 expression has been
associated with prolonged disease-free survival in ag¬
gressively treated lymphomas (Schuurman et al 1988). Thus
although a large panel of MCA provides only a limited
amount of additional information which is of use to the
diagnostic pathologist it is possible that the variation
of antigen expression is associated with clinically
important parameters. The next stage of the study was
therefore to correlate the clinical presentation and
follow up of the series of B-cell NHL phenotyped in an
attempt to determine whether detailed phenotyping using
such a panel of MCA against antigens whose expression is
associated with activation, cell-cycle transit, and
differentiation provides additional clinically useful
information.
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5.2 MATERIALS AND METHODS
5.2.1 Cases and Clinical Data
Clinical follow-up was obtained from case notes of 111
cases of B cell NHL analysed in Chapter 4, clinical data
being unobtainable on 37.
5.2.2 Histological Classification and Immunophenotvoing
Cases were classified by the Kiel Classification and
Working Formulation. Immunophenotyping was by indirect
immunoperoxidase as detailed in Chapter 2.
5.2.3 Statistical Analyses
Correlation between antigen expression, histology and
clinical behaviour was only undertaken for markers in the
"restricted B-cell", and "activation - associated" groups
of antigens. The antigens in these two groups showed
most variation of expression in the initial immunopheno-
type analysis, strongly positive and weakly
positive/negative subsets could readily be identified for
comparison. The "pan-B-cell" and MHC Class II antigens
were expressed by the large majority of lymphomas and
correlations between positive and negative subsets could
not be made.
In Chapter 4 antigen expression was assessed in a semi-
guantitative manner with strongly (> 70% cells staining),
moderately (30 - 70%) and weakly (5 - 30%), positive or
negative groups being identified. For statistical analy¬
sis in this component of the study groups were separated
into moderate to strongly positive (>30% positive) and
weakly positive/negative subsets (<30% positive).
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5.3 RESULTS
5.3.1 Histology and Clinical Features
A total of 111 cases were studied. The histological
classification and clinical features are summarised in
Table 5.1 with more detailed results of each of the
separate morphological groups in Tables 5.2 - 5.7 (pages
125-131). Two cases classified as plasmablastic lympho¬
mas were included in the immunoblastic group for analysis
as high grade tumours of terminally differentiating
cells. Three cases of follicular centroblastic lymphoma
were classified as high grade Kiel.
The series included 64 males and 47 females, age range
15-88 (mean 59 years). The majority of cases showed
disseminated disease at presentation (11 Stage 1, 10
Stage II, 20 Stage III, and 67 Stage IV, 3 not staged).
63 of 109 cases showed bone marrow involvement.
Cases were treated by a number of different therapeutic
regimes. These have been grouped as simple or aggres¬
sive. Simple therapies were those not intended to induce
remission and included surgery, radiotherapy and or
simple drug regimes (chlorambucil ± prednisolone ± vin¬
cristine) . Aggressive therapy included drug regimes
designed to achieve complete remission (CHOP ± bleomycin,
BACOD, MOPP, MVPP, CH1VPP M-PEEC, MCHOP ± bleomycin).
44 cases were given simple therapy and 67 cases given
aggressive therapy. Kiel high grade tumours were more
often treated aggressively (36 of 42) than low grade
tumours (31 of 69) . There was a strong correlation with
type of therapy and induction of complete remission (p <
0.00001), but none between grade of lymphoma and induc¬
tion of remission.
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5.3.2 Immunophenotype Analyses and Clinical Correlation
The immunotypes of the cases available for clinical
correlation are summarised in Table 5.8. Detailed analy¬
sis of these cases is available in Chapter 4. Low grade
lymphomas expressed CD5 (p< 0.0001), CD10 (p< 0.05) and
CD23 (p< 0.001) significantly more often than high grade
tumours. CD38 (p< 0.01), CD71 (p< 0.0001) and 4F2 (p<
0.05) were more frequently expressed by high grade le¬
sions .
There was no association between antigen expression and
clinical findings including stage, bone marrow involve¬
ment or response to therapy.
5.3.3 Survival Analyses
The results are given in Tables 5.9 and 5.10.
5.3.3.1 Clinical Data
A number of clinical parameters were associated with
better survival. (Table 5.9). These included age less
than 60 (p < 0.001, figure 5.1), stage at presentation (p
< 0.01, figure 5.2) and response to therapy (p < 0.00001,
figure 5.3). There was no association between survival
and sex or bone marrow involvement.
5.3.3.2 Histology
Histological grading showed significant correlation with
survival (Table 5.9) for both Kiel (p < 0.015, figure
5.4) and WF (overall p < 0.0001; low v intermediate p <




Survival was correlated with expression of individual
markers for 1) all cases 11) cases within histological
grades, WF and Kiel, and 111) cases given aggressive
therapy. The results are summarised in Table 5.10.
There were significant associations between expression
of 4F2 (p < 0.01 figure 5.6) and CD71 (p < 0.015 figure
5.7) and survival with all cases included. Expression of
4F2 by low grade tumours was associated with a shortened
survival in Kiel (p < 0.05 figure 5.8) but not WF (figure
5.9) whereas CD71 expression and survival in low grade
lymphomas reached significant levels with WF (p < 0.05
figure 5.10) but not Kiel (figure 5.11). As almost all
high grade lymphomas expressed 4F2 and CD71 it was not
possible to undertake separate analysis of this group.
There was no significant association with survival and
the other antigens studied before or after histological
grading. There was no association between survival and
antigen expression in the group of NHL given * aggressive'
therapy.
5.3.3.4 Multivariate Analysis
The association between both 4F2 and CD71 and survival
was independent of age, Kiel Classification and stage (p
< 0.05), but not WF. When 4F2 and CD71 were included
together CD71 was not independent of 4F2 as a prognostic
marker.
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25/67323 52917 30/ 8 1/423/45 364 23242/ 1
0/1912/684655/ 3/2519/4142 20/
W.F. Lowgrade Intermediategra e Highgrade
14/4827 61 58 2157/48 12/485 96/448 22 251/ 7 0/1431 2/794
0/1810/47337 2/1714/4841 95 1/97/144 113/ 3
*Includes3follicularcentrob asticlymph maw ichergroup dashighg atu o s byKielClass fication.
Table 5.9 Median survival of cases when separated by
clinical features and histological grade.
Clinical Data No. of Median Survival
Cases (Months) Sianificance
Age < 60 51 50. 3 p < 0.001
> 60 60 17.0
Staae I 11 50. 0+ p < 0.01





NR 44 9.0 p < 0.00001
PR 38 25.1
CR 28 62 . 0+
Sex M 64 30.5 NS
F 47 23 . 3
Bone Marrow
Neg 63 33 . 6 NS
Pos 46 23 . 5
HISTOLOGY




HG 14 6 p < 0.0001
IG 49 19.7
LG 48 69+
HG = high grade, IG = intermediate grade, LG = low grade.
NS = not significant.
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Tails5.10 Mediansurvival(mo ths)fcasesexpre singd ff rentntige s.Survivalanalysiswam deor)cases,i)fterhistologicalgradingi )rc sesiv nhe apynt ndedoin uceremission.Comparisonfortati ticalalysesweremadebetw ngroupsith<30%nd>c llsstaining. ANTIGEN EXPRESSION CDS<30% >30% CDS<30% >30% CD10<30% >30% CD33<30% >30% CD21<35% >30% CD23<30% >30% CD25<30% >30% CD30<30% >30% CD71<30% >30% 4F2<30% >30%ALL 24.5(83)ns 30.0(26) 22.0(64)ns 31.7(45) 24.0(73)ns 27.0(28) 30.7(78)ns 18.3(31) 48+(13)ns 22.7(39) 18.5(41)ns 30.9(18) 25.9(87)ns 22.2( ) 13.5(41)ns 26.5(3) 69+(23)p<0.015 21.9(88) 69+(15)p<0.01 22.3(95)KIEL(Grade)MedianSurvival(no.ofcases) WORKINGF RMULATION(Grade)





































































Figure 5.1 Survival of B-cell NHL separated by age.
Time(Months)
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Figure 5.2 Survival of B-cell NHL separated by stage at
presentation.
Stage I and II (21)
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Figure 5.6 Survival of B-cell NHL separated by expres¬
sion of 4F2.
0 18 36 54 72
Time(Months)
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Figure 5.8 Survival of B-cell NHL (low grade Kiel)
separated by 4F2 expression.
Time(Months)
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Figure 5.9 Survival of B-cell NHL (low grade Working
Formulation) separated by 4F2 expression.
Tlme(Months)
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Figure 5.10 Survival of B-cell NHL (low grade Working
Formulation) separated by CD71 expression.
Time(Months)
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Figure 5.11 Survival of B-cell NHL (low grade Kiel)




A large number of antibodies are available for immunophe-
notyping lympho-proliferative lesions. Immunophenotyping
is useful in clinical practice to distinguish between
lymphoid and non-lymphoid neoplasms, reactive and neo¬
plastic lymphoid proliferation, and for determining T or
B-cell lineage of NHL. When a large panel of antibodies
is used for phenotyping B-cell NHL only a relatively few
consistent features of antigen expression are seen, eg.,
CD5 is expressed by lymphocytic and centrocytic NHL and
rarely by other B-cell tumours (Chapter 4, Schuurmann et
al 1987).
Previous studies have shown correlation with antigen
expression and clinical behaviour. 4F2 and CD71 expres¬
sion is associated with poor prognosis in NHL (Habeshaw
et al 1983, Holte et al 1987, Pileri et al 1984). The
results presented here confirm these observations. No
association could be found between clinical behaviour and
expression of other activation and differentiation asso¬
ciated antigens studied. Both 4F2 antigen and CD71/trans-
ferrin receptor are expressed more freguently by histo¬
logically high grade tumours whose overall prognosis is
known to be poor. Expression of these antigens can
therefore in part be predicted by histology, but multi¬
variate analysis shows that the association with survival
is independent of age, stage and Kiel histological grade.
Expression of 4F2 antigen and CD71 was also associated
with clinical behaviour of low grade tumours but reached
significant levels only in the Kiel classification with
4F2 and in the WF for CD71. These markers may therefore
be useful for predicting clinically poor prognostic cases
of low grade lymphomas.
A large number of statistical analyses were undertaken in
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this study and at a 5 per cent significance level signif¬
icant results could be seen by chance in 1 of 20 tests.
The tests with significant associations were mostly at
the p<0.01 level. Within the low grade groups statisti¬
cally significant results were marginal with both CD71
and 4F2 (p<0.5) and although could be accounted for by
chance alone the trends in the survival curves suggest
that these are truly significant results. The borderline
nature of the results is probably secondary to the small
numbers in each group.
Other membrane associated antigens have been shown to
have prognostic significance. CD10 myelomas behave
aggressively (Durie and Grogan 1985), but in our series
of B—NHL there was no significant correlation between
expression of this antigen and survival. This is proba¬
bly in part because of the large number of low grade
follicular lymphomas we see expressing CD10 and few cases
of lymphoblastic lymphoma (often CD10 positive (Ritz et
al 1981)) in our series.
CD23 expression has been associated with prolonged re¬
lapse free survival in NHL (Schuurmann et al 1988). This
is not unexpected as it is expressed predominantly by low
grade lesions. An association between CD23 and survival
could not be confirmed in this study. These results may
in part be accounted by the poor survival of centrocytic
lymphomas in our series. Schuurman et al (1988), corre¬
lated the expression of a panel of markers similar to
that used in this study (including CD9, CD10, CD21, CD23,
CD25, and CD71) with relapse-free survival in cases of
NHL given therapy intended to achieve complete remission.
This form of treatment was given to only 65 of our cases.
When these were analysed separately we were still unable
to show an association between survival and CD23 expres¬
sion or other markers. This may in part be a reflection
of the larger proportion of low grade lymphomas given
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aggressive therapy in the study of Schuurman et al
(1988) .
While immunophenotyping of NHL has allowed greater under¬
standing of the biology of this group of neoplasms and is
an invaluable research tool, the clinical application
and usefulness of many of the antibodies used for pheno-
typing lymphoid cells is in doubt. A limited panel of
antibodies which aids identification of lymphoid neo¬
plasms and helps ascertain lineage of these tumours is
probably all that is necessary for routine clinical use
at present. New markers need to be developed which will
differentiate between good and poor prognosis cases in
histological grades, allowing the pathologist to make
more accurate predictions of behaviour of NHL. The
results presented suggest that 4F2 and CD71 may identify
poor prognostic cases of histologically low grade NHL.
Immunostaining for the proliferation marker Ki67 may
allow similar discrimination (Hall et al 1988). The
number of different chemotherapeutic regimes given to a
series of NHL in a retrospective study such as this
creates some problems in assessment of associations
between phenotype and clinical behaviour but the identi¬
fication of potentially useful markers such as 4F2, and
CD71 suggests a need for immunophenotypically identified
antigens as well as histological grade to be taken into
consideration in prospective trials of the efficacy of
different treatment modalities in the management of NHL.
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APPENDIX
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following papers:-
1) Salter DM, Krajewski AS, Cunningham S. (1988). Activa¬
tion and differentiation antigen expression by B-cell
non-Hodgkin1s lymphoma. J Pathol 154;209-222.
2) Salter DM, Krajewski AS, Sheehan T, Turner G, Cuthbert
RJG, McLean A. (1989). Prognostic significance of activa¬
tion and differentiation antigen expression in B-cell
non-Hodgkin•s lymphoma. J Pathol. 159: 211-220.
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SUMMARY
In an attempt to establish whether extended immuno-phenotyping allows more accurate definition of subgroups of
B-cell non-Hodgkin's lymphoma (NHL) we have stained a series of 145 cases with a large panel of monoclonal
antibodies that recognize B-cell differentiation and activation antigens. No antigen was expressed by all cases. The B-
cell histogenesis in many cases could be confirmed only by using a panel of immunoglobulin and pan B-cell markers.
There was marked phenotypic heterogeneity within and between major groups of B-cell NHL as delineated by the Kiel
classification although the differentiation antigens CD5 (lymphocytic and centrocytic NHL) and OKTIO (plasma cell
tumours) were more often expressed by certain morphological groups. The activation antigens 4F2 and transferrin
receptor were expressed more strongly and more often by high grade NHL but other activation antigens (CD23 and
CD25) were not more frequently associated with these tumours. Extended phenotyping may be of value in improving
the understanding of biological abnormalities and processes involved in B-cell NHL, but we conclude that a limited
panel ofmarkers (CD3, CD5, CD22, CD45, IgM, kappa, and lambda) should be sufficient for routine diagnosis and
classification ofmost cases.
key words—B-Cell non-Hodgkin's lymphoma, activation antigens, differentiation antigens, monoclonal antibodies.
INTRODUCTION
Non-Hodgkin's lymphomas (NHL) are believed
to result from proliferation and accumulation of
lymphoid cells at different stages of differentiation.
Currently used classifications of NHL, such as the
Kiel classification, are based on the belief that
the morphology and immunophenotypes of NHL
correspond to normal cells at varying stages of dif¬
ferentiation and activation ranging from lymphoid
precursor cells to terminally differentiated T or
B cells, e.g., lymphoblastic NHL—immature
pre-B/thymic T cells; centroblastic/centrocytic
NHL—follicle centre cells; immunoblastic NHL
and plasmacytoma—terminally differentiated cells.
Previous studies have shown some correlation
between antigen expression and certain morpho¬
logical features of B-cell NHL1 ~4 but only a rela¬
tively limited number of anti-B-cell monoclonal
Addressee for correspondence: Dr D. M. Salter, University
Medical School, Edinburgh EH8 9AG, U.K.
0022-3417/88/030209-14 $07.00
© 1988 by John Wiley & Sons, Ltd.
antibodies (MCA) were used. A large number of
MCA which react with B-cell associated antigens
expressed at different stages of differentiation and
activation have now been identified5 and it is poss¬
ible that the differential expression of such antigens
may allow a more accurate definition of the subtypes
ofNHL within morphologically similar groups. We
report here the results of a study in which we have
investigated this possibility.
MATERIALS AND METHODS
The cases described in this study include all cases
of B-cell NHL diagnosed in the Immunopathology
Laboratory, Edinburgh University Pathology
Department during the period August 1984 to
December 1986 and all cases of B-cell NHL diag¬
nosed during the period July 1982 to July 1984 in
which tissue blocks had been stored at — 70°C.
Tissue was received fresh from the operating
theatre. Representative portions were taken for
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Table I—Antibodies used in this study
Mol. wt of antigen
Antibody (kD)/CD number Source Ref.
Anti-immunoglobulin
Anti-kappa Dakopatts
Anti kappa-FITC/anti kappa-TRIC Kallestad
Anti lambda Dakopatts
Anti lambda-FITC/anti lambda-TRIC Kallestad
Anti IgM/DA6127/anti IgM-FlTC Dakopatts/K. Guy/Kallestad
Anti IgD-FITC Kallestad
Anti IgD/anti IgG-FITC Dakopatts/Kallestad
Anti IgA/anti IgA-FITC Dakopatts/Kallestad
'Pan' B cell
HD37 40/CD19 Dakopatts 7
B1 35/CD20 Ortho 8,9
Dako-B 135/CD22 Dakopatts 10
F8-11-13 220/CD45R J. Fabre 6,11
'Restricted' B cell
Leu 1 65/CD5 BD 12
FMC8 24/CD9 H. Zola 13
Dako Calla 100/CD10 Dakopatts 14
OKTIO 45/NA Ortho 9,15
'Activation-associated'
S/RFB6 140/CD21 SAPU 16,17
MHM6/101B7 45/CD23 J. Gordon/Dakopatts 7,18
Dako-IL2-R 55/CD25 Dakopatts 19-21
Dako-Kil 116,126/CD30 Dakopatts 22,23
OKT9 90/NA(Trf-R) Ortho 24
4F2 40,80/NA K. Guy 25
MHC class II
L243 DR S. Howie (ATCC) 26
B7/21 DP I. S. Trowbridge 27
Leu 10/Tu22 DQ BD/A. Ziegler 28,29
BD = Becton Dickenson, NA = not allocated, SAPU = Scottish Antibody Production Unit, Trf-R = transferrin
receptor, ATCC = American Tissue Culture Collection.
cryostat sections and for formalin fixation and
paraffin embedding. Cryostat sections were cut at
3—4 /urn from either fresh frozen material or blocks
stored at — 70°C. Immunohistochemical staining
was by an indirect immunoperoxidase technique
as described fully elsewhere.6 In some cases, the
presence of monoclonal immunoglobulin was also
demonstrated by direct immunofluorescence on





The B-cell associated antibodies used in this study
are shown in Table I. The antigens they recognize
can be broadly separated into five main groups: (a)
immunoglobulin; (b) 'pan' B-cell antigens which are
expressed early in B-cell ontogeny and lost at a
pre-plasma cell stage; (c) 'restricted' B-cell antigens
which although not lineage-specific are expressed
at limited stages of B-cell differentiation; (d)
'activation-associated' antigens; these include anti¬
gens, such as CD21, which are present on resting
B cells and lost following activation; the other
activation-associated antigens (CD23, 25, 30,
transferrin receptor (Trf-R), and 4F2) are absent
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Table II—Histological type, number and biopsy site of B-cell NHL studied
Site
Lymph GI
Diagnosis No. node Spleen tract Other
Lymphocytic 19 17 1 — 1
Lymphoplasmacytoid (immunocytoma) 2 1 — — 1
Prolymphocytic 4 1 2 — 1
Hairy cell leukaemia 3 — 3 — —
Centrocytic 12 7 3 1 1
Follicular centroblastic/centrocytic 39 36 1 — 2
Diffuse centroblastic/centrocytic 11 8 — 2 1
Centroblastic 32 22 — 2 8
Immunoblastic 14 10 — 1 3
Plasmacytic (plasmacytoma) 7 3 — — 4
Lymphoblastic 2 — 1 — 1
Total 145 105 11 6 23
from resting cells but their expression can be
induced following stimulation of B cells by anti¬
immunoglobulin or mitogens; and (e) major histo¬
compatibility complex (MHC) class II antigens. In
addition, all cases were stained with and (apart
from reactive T cells) found to be non-reactive with
the pan T-cell anti-CD3 antibody Leu 4 (Becton
Dickinson30).
RESULTS
A total of 145 B-cell NHL were studied. The
numbers in each histological group and anatomical
site of biopsy are shown in Table II.
Lymphocytic lymphoma
Nineteen cases of lymphocytic lymphoma were
studied (Fig. 1) derived from lymph nodes (17),
spleen (1), and breast (1). All cases expressed
monotypic immunoglobulin: 17 expressed IgM with
coexpression of IgD in eight and IgG in one; one
case expressed IgG alone and onemonotypic kappa
light chain without heavy chains. The pan B-cell
markers CD 19, CD22, and CD45R were strongly
expressed by all cases. The CD20 marker B1 showed
variable and often weak staining between and
within cases. All cases tested expressed the CD5
antigen. CD9 was variably expressed in 11 cases.
Staining was strongest outside proliferation centres.
There was no staining for CD 10 or OKTIO. The
CD21 antigen (C3d receptor) was expressed by the
majority of cells in all cases. Lymphomas which
expressed IgMD tended to show stronger reactivity
than those expressing IgM alone. CD23 was
expressed by the majority of cells in seven cases and
by a minority in one. CD25, the interleukin 2 recep¬
tor (IL2-R), was expressed weakly by the majority
of cells in eight cases and by a proportion in two
others. There was no expression of CD30 in the
three cases tested. The transferrin receptor and 4F2
were variably expressed: in some cases both antigens
were expressed by the majority of cells while in
others only a proportion ofcells stained. Expression
of both antigens was enhanced in proliferation
centres. All cases expressed HLA DR and DP
antigens with absent or low DQ expression in a
proportion of cases. MHC class II expression was
enhanced in proliferation centres.
Lymphoplasmacytic lymphoma (immunocytoma)
Two cases—one nodal and one soft tissue mass—
were studied. The nodal case was IgM positive with
a phenotype similar to that of small lymphocytic
lymphomas expressing CD22, CD45R, and MHC
class II antigens but not CD5. The other case was
IgGK positive and showed loss of pan B-cell anti¬
gens and CD5 with decreased MHC class II antigen
expression. The OKTIO antigen was not expressed
by either tumour.
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Prolymphocyte lymphoma
Four cases were available for study, these being
from spleen (2), lymph node (1), and orbit (1). All
cases expressed IgM together with IgD or IgG in
two cases. All cases expressed pan B-cell antigens
although expression ofCD20 was weak in one. Two
cases expressed CD5 strongly, one weakly, and one
was negative. None expressed CD9, CD 10 (three
cases), or the OKTIO antigen. CD21 was expressed
strongly by one case and by a minority of cells in
the other studied. Neither of the two cases studied
expressed CD23, and only 1 /4 cases expressed CD25
weakly. The one case tested did not express CD30.
Both transferrin receptor and 4F2 were strongly
expressed by all four cases. DR and DP were
strongly expressed by all four cases, but DQ was
expressed by only a proportion of cells in three
cases.
Hairy cell leukaemia
All three cases of hairy cell leukaemia studied
were resected spleens. All were kappa positive with
one IgMA, one IgMD, and one IgG positive. They
expressed the pan B antigens CD 19, 20,22, and 45R
but not CD5. One was CD9 positive. Two expressed
CD 10 weakly in the cytoplasm. None of the cases
expressed the OKTIO antigen but one was positive
for CD23 and all expressed the CD25 antigen.
Neither of the two cases tested expressed CD30.
Transferrin receptor and 4F2 expression were weak
or absent in 2/3 cases. DR and DP were strongly
expressed by all three cases whereas only two
showed DQ expression.
Centrocytic lymphoma
Twelve cases of centrocytic lymphoma were
studied from lymph nodes (7), tonsil (1), spleens (3),
and small intestine (1) (Fig. 2). All expressed mono-
typic IgM, and 5/10 tested coexpressed IgD. Five
cases expressed lambda and seven kappa light
chains. All cases tested stained strongly for pan
B-cell antigens and CD5. CD9 was expressed by a
proportion of cells in seven cases. None expressed
CD 10 and only a proportion of cells in two cases
expressed OKTIO. All five cases tested were CD21
positive and CD23 negative. Two cases showed
weak expression of CD25 but not CD30. Numbers
of cells staining with 4F2 and transferrin receptor
varied between cases. In most cases, staining was
weak or restricted to a minority of cells. Although
DR and DP were expressed strongly in all cases, DQ
was often absent or weak
Follicular centroblastic/centrocytic lymphomas
A total of 39 cases were studied (Fig. 3) from
lymph nodes (36), spleen (1), thyroid (1), and breast
(1). Twenty-three cases expressed kappa, 14 lambda
light chains, and in two cases immunoglobulin
staining was negative or equivocal. Thirty cases
expressed IgM with coexpression of IgD (3), IgG
(1), and IgA (1): six cases expressed IgG alone and
one lacked heavy chains but expressed lambda light
chain. The majority of cases expressed pan B-cell
antigens strongly and were CD5 negative. CD 10
(24/36) and OKT10 (13/38) were variably expressed.
CD9, CD21, and CD23 were also variably
expressed, although assessment of their expression
was complicated by strong dendritic reticulum cell
(DRC) staining. CD25 was expressed by neoplastic
cells in only 2/36 cases. None of the cases tested
expressed CD30. 4F2 and the transferrin receptor
showed similar but variable expression between
cases although in some cases there was differential
expression, e.g., strong expression of 4F2 and weak
with transferrin receptor or vice versa. The majority
of the cases expressed DR, DP, and DQ, although
DQ expression was often reduced or absent.
It was not possible to correlate variation in cellular
content of follicles (i.e., proportion of centroblasts
to centrocytes) with any particular phenotype.
Diffuse centroblastic/centrocytic lymphoma
Eleven cases of diffuse centroblastic/centrocytic
lymphoma were studied (Fig. 4) derived from lymph
nodes (8, two of which had extranodal spread),
small intestine (2), and omentum (1). Eight cases
expressed IgM together with IgD in two instances.
Three cases expressed IgG, one without light chain.
The majority of cases expressed pan B-cell antigens
CD 19, 22, and 45R whereas in a few cases CD20
expression was weak or absent. None of the cases
was CD5 or OKTIO positive. Two cases expressed
CD9 and a further two CD10. CD21 was expressed
by the majority of lymphoid cells in only two cases
with DRC stained in 4/5 cases. CD23 was expressed
by the majority of cells in 2/6 cases but CD25 stain¬
ing was observed in only one case. Neither of the
two cases tested expressed CD30.4F2 was expressed
strongly in all cases whereas transferrin receptor
staining was seen on only a minority of cells in four
cases. The MHC class II antigens DR, DP. and DQ
were strongly expressed in all cases.
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Figs 1-7—The histograms illustrate the percentage of cases showing the estimated population of malignant
B-cell staining. H = > 70 per cent. 63 = 30-70 per cent, □ = 5-30 per cent of cells staining positively
Centroblastic lymphomas
Thirty-two cases ofcentroblastic lymphoma from
lymph nodes (22), stomach (2), testis (2), omentum
(1), mediastinum (1), tonsil (1), retroperitoneum (1),
breast (1), and scalp (1) were studied (Fig. 5).
Seventeen cases expressed kappa, eight lambda light
chains, and one case gave equivocal results. One
case expressed IgM heavy chain without light
chains. Fourteen cases expressed IgM, one with
IgD, ninewith IgG, and threewith IgA; five cases did
not express immunoglobulin-. While the majority of
cases expressed pan B-cell antigens strongly, a few
cases showed loss of one or more of these antigens.
CD5 expression was uncommon (1/32 cases). There
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was variable expression of CD9, CD 10, and OKTIO
antigens. No relationship was observed between the
expression of these antigens, with all possible per¬
mutations being seen within the series. Twelve of 17
cases tested expressed CD21 although the intensity
ofstaining was often weak in comparisonwith other
lymphomas. Only one of 19 cases tested showed
more than a minor population of cells or DRCs
expressing CD23. CD25 and CD30 were expressed
by a minority of cases only, whereas 4F2 and
transferrin receptor were strongly expressed by the
majority. DR, DP, and DQ were expressed strongly
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by most of the cases, although a few showed loss of
one or more antigens.
Within this group 2 'special' centroblastic sub¬
types were recognized. In one, a sclerosing medias¬
tinal lymphoma in a young female expressed IgAK,
pan B-cell, and HLA class II antigens. In the other,
five cases contained a large proportion of multi-
lobated cells expressing pan B-cell antigens and
OKT10 antigen; in two cases tested, these cells were
CD21 positive and CD23 negative. None expressed
CD9.
Immunoblastic lymphomas
Fourteen cases of immunoblastic lymphoma
were studied (Fig. 6) and included two cases of poly¬
morphic immunocytoma containing an admixture
of plasma cells and plasmablasts with a predomi-
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nance of immunoblasts. Ten cases were lymph
nodes and four extranodal (1 retroperitoneum, 1
chest wall mass, 1 knee, and 1 spleen). Eleven cases
expressed kappa and three lambda light chains.
Eight expressed IgM together with IgD and in one
case with IgA. Five cases expressed IgA alone and in
one case IgA and IgG were coexpressed. There was
variable expression ofpan B-cell antigens. CD22 and
CD45R were most commonly expressed; however,
these and other pan B-cell antigens were often lost or
only expressed by a minority of tumour cells. CD5
and CD9 were not expressed. CD 10 staining was
observed in only one case and this tumour, although
showing a vastmajority of immunoblasts, contained
in addition a population of large centrocytes and
centroblasts suggesting derivation from a diffuse
centroblastic/centrocytic lymphoma. Almost half
of the cases showed reactivity with OKTIO. This
was strongest in polymorphic immunocytoma and
in cases showing plasmablastic differentiation.
However, a few cases showing plasmacytoid differ¬
entiation did not express the OKTIO antigen. CD21
was expressed by a minority of cases and CD23 was
expressed weakly by themajority of cells in only one
case tested. Staining for CD25 was inconsistent,
whereas both 4F2 and transferrin receptor were
strongly expressed by all cases. In one case, the
majority of cells expressed CD30 and in two others,
a minority of large blast cells were positive. The
MHC class II antigens DR, DP, and DQ were
strongly expressed in all cases.
Plasmacytic lymphoma (plasmacytoma)
Seven cases were studied (Fig. 7) from lymph
nodes (3) and extranodal tissues (1 scalp, 1 sacral
tumour, 1 epidural tumour, and 1 testicular
tumour). Six expressed kappa and one lambda light
chain. All seven expressed IgG, one in association
with IgA. All of the cases tested had lost CD19 and
CD20 while CD22 was expressed by a proportion of
cells in two cases. CD45R expression was observed
by a majority of cells in four cases. All cases
expressed OKTIO antigen and 4/7 expressed CD9.
None of the cases tested expressed CD5, CD10,
CD21, CD23, or CD30, and only one showed weak
expression of CD25. The MHC class II antigens
were lost by 6/7 cases although one did contain a
minor population of class II positive plasma cells.
Lymphoblastic lymphomas
Only two cases morphologically diagnosed as
lymphoblastic lymphomas were available for study.
One was an epidural tumour and the other a spleen.
Both were terminal deoxynucleotidyl transferase
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positive. One case did not express immunoglobulin
and the othermonotypic IgM lambda. The immuno¬
globulin negative case expressed CD 19, CD22, CD9,
and CD 10 but none of the other pan B-cell or B-cell
differentiation associated antigens including MHC
class II. The other case expressed all four pan B-cell
antigens, CD9, CD10, OKTIO, and MHC class II
antigens but did not express CD21 or CD23. Both
cases were strongly 4F2 and transferrin receptor
positive.
DISCUSSION
The present study reports the phenotypic expres¬
sion of a series of B-cell NHL using an extended
panel of MCA against B-cell differentiation and
activation antigens. We were able to identify marked
phenotypic heterogeneity both within and between
the major morphological subgroups recognized by
the Kiel classification.
No single marker in our panel reacted with all
cases tested. The B-cell histogenesis of our cases was
confirmed by demonstrating the presence of either
monotypic immunoglobulin light chains or the
expression of one or more pan B-cell restricted
antigens. A few cases, predominantly within the
centroblastic and lymphoblastic groups, failed to
express immunoglobulin and showed variable
expression ofpan B-cell antigens. In immunoglobu¬
lin negative cases, at least one or more pan B-cell
antigens could be demonstrated. Similar findings
have been reported by others.2,3'31,32 The finding
that Bl, which recognizes CD20, failed to stain or
showed weak reactivity in a number of our cases
confirms previous observations ofpoor reactivity of
this antibody in tissue sections.7,31'33 This may be a
technical artefact, as strong reactivity is seen when
cell suspensions are employed.2 Earlier reports have
shown that 'null' cell tumours expressing neither
surface immunoglobulin nor sheep erythrocyte
receptors constitute approximately 5 per cent of
NHL.34,35 Many such cases have been shown to be
of B- or T-cell lineage by immunogenotyping.36,37
Using an extended panel of anti-B-cell MCA and a
similar panel of anti-T-cell and macrophage MCA,
we have been able to assign every case of approxi¬
mately 250 NHL seen in our laboratory over the
last 4 years to either B-cell, T-cell, or macrophage/
histiocyte lineage, suggesting that 'null' cell tumours
are rarely seen (unpublished observation).
Four of the MCA used in our panel are known to
recognize antigens (CD5, CD9, CD 10, and OKTIO)
expressed at variable or multiple stages of B-cell
differentiation. These are potentially useful for
defining subgroups of B-cell NHL immunologically
and for comparison with normal cellular counter¬
parts. CD5, an antigen expressed predominantly by
T cells,12 has been shown recently to be expressed
by mantle zone B cells38 and fetal primary follicle
B-cells.39 In our series, CD5 expression was
restricted predominantly to lymphocytic and
centrocytic lymphomas, confirming the findings of
others.2,3,38,40"42 We also identified a small
number of cases in follicular centroblastic/
centrocytic, centroblastic, and prolymphocytic
groups which were CD5 positive. Small numbers of
follicular lymphomas have previously been reported
as CD5 positive.2,3,32 The finding that prolympho¬
cytic lymphoma was frequently CD5 positive agrees
with Stein et al.3 but contrasts with Gobbi et al.,43
who found 12 cases ofprolymphocytic leukaemia to
be CD5 negative. The latter studies employed RFA-
2 on suspensions of peripheral blood cells and may
reflect differences in antigen expression between
neoplastic cells in tissues and blood. Alternatively,
histologically recognized prolymphocytic lym¬
phoma may be a different disease entity from
prolymphocytic leukaemia.
CD9, which reacts with a proportion of germinal
centre cells44,45 and approximately 10-20 per cent of
mantle zone cells44 in reactive lymph nodes, showed
variable reactivity in all groups studied, except
immunoblastic lymphomas which were always
negative. It was therefore not of value for subtyping
B-cell NHL whereas others, using a different CD9
MCA (BA-2), have suggested this antigen may be
selectively expressed by mantle-zone lymphomas.42
In lymphocytic lymphomas, expression ofCD9 was
either absent or reduced in proliferation centres,
suggesting that this antigen reflects a stage of
activation rather than differentiation.
CD 10 expression by lymphoblastic lymphomas is
well recognized,46 and expression by reactive follicle
centre cells has recently been described.3,44,45 Our
results confirm the expression of this antigen by at
least a proportion of neoplastic follicle centre cell
tumours.2,3,47,48 CD10 positivity has been shown
to correlate with more aggressive myeloma.49 This
raises the possibility that the variable expression of
CD 10 in cases of centroblastic and immunoblastic
lymphoma seen in our study represents similar
aggressive subgroups.
In normal lymphoid tissue, OKTIO is a marker
of plasma cells9,15 and stains follicle centre cells
but not mantle zone cells.9,43"45 OKTIO showed
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corresponding reactivity in our series, staining a
proportion of follicular lymphomas and plasma¬
cytomas as previously documented.2,43 Similarly,
reactivity with B-cell lymphoblastic lymphomas has
been described.43 Although OKTIO positivity fre¬
quently correlated with plasma cell differentiation
histologically, in two cases of lymphoplasmacytoid
lymphomas (immunocytoma) this antigen was not
expressed. Unlike other plasma cell tumours, these
cases expressed MHC class II antigens and in one
case pan B-cell antigens. In contrast to lymphocytic
lymphomas, they were CD5 negative. Other workers
have also recognized the distinct phenotypic
characteristics of this group of NHL and have
postulated that they may represent proliferations of
a subpopulation of lymphoid cells.38'50
OurpanelofMCA included some which recognize
'activation-associated' antigens. CD21, the C3d
receptor,51,52 is present on resting B cells but is lost
following in vitro activation;53,54 others, such as
CD23, CD25, CD30, transferrin receptor, and 4F2,
are absent from resting cells but can be induced by
mitogens.21,23,25,55 - 57 Expression of one of these
antigens, the transferrin receptor, has been shown to
be correlated with histological grade and clinical
outcome ofNHL.58,59 In nearly all the cases tested,
at least a proportion of neoplastic cells were acti¬
vated, as shown by expression ofCD23, transferrin
receptor, or 4F2. Many cases also expressed CD21,
an antigen lost rapidly following activation of
splenic B cells by anti-Ig.17,54 Other workers have
reported similar heterogeneity in expression of
CD21 (B2)31,32 and it is possible its expression by
activated cells represents abnormal regulation in
neoplastic cells.
CD23 is expressed within 3 h following activation
of resting B cells, before cells enter the cell cycle.56,57
In reactive lymph nodes and tonsil, it is expressed at
variable intensity by mantle zone lymphocytes and
a proportion of DRC7 but not by germinal centre
cells. CD23 was maximally expressed by the low
grade lymphomas (lymphocytic lymphomas) and
infrequently expressed by high grade (centroblastic
or immunoblastic) tumours. Other workers have
made similar observations3,38 and it is possible that
CD23 is expressed only transiently during B-cell
activation and is lost after a certain stage of com¬
mitted differentiation. Failure of germinal centre
cells to express CD23 would support this idea.
The observation that lymphocytic lymphomas were
CD23 positive whereas centrocytic lymphomas were
negative is consistent with previous observations3
and may be a useful means of differentiating these
subtypes, although other workers have reported
CD23 positive centrocytic lymphomas.48
CD25 (IL2-R) was initially shown to be expressed
by activated T cells.19 Recent work, however,
has also demonstrated its expression by activated
normal B cells20,21 and by hairy cell leukaemia.60,61
Our results show that CD25 is also variably
expressed in most histological groups of B-NHL
although there was no correlation with histological
grade. Chronic lymphocytic leukaemia cells pro¬
liferate and differentiate in response to IL262,63 and
it is possible that the growth of at least some B-cell
lymphomas is regulated through abnormal receptor
expression and stimulation by IL2.
CD30 (Kil) was initially described as reacting
selectively with Reed-Sternberg cells in Hodgkin's
disease and with a small population of large cells in
reactive lymph nodes.22 Recent work has shown
that CD30 can be induced in B cells by mitogens
and infection with Epstein-Barr virus.23,24 CD30
was present in only a small number of high grade
lymphomas (centroblastic or immunoblastic) in this
series, consistent with the findings of others.23
The activation-associated antigens 4F2 and
transferrin receptor were most strongly expressed
by high grade lymphomas and less often and more
weakly by low grade lymphocytic and follicular
lymphomas. Increased expression of transferrin
receptor in high grade lymphomas has been shown
previously,58,59 but our results demonstrate more
heterogeneity in low grade lymphomas than has
been previously described.
The expression of MHC class II antigens extends
and confirms results previously published by us and
others,64-66 with coordinate and non-coordinate
expression of DR, DP, and DQ being evident in
many histological groups. The increased expression
of class II antigens in the proliferation centres of
lymphocytic lymphomas and in vitro following entry
of B cells into the cell cycle67 suggests that these
antigens are involved in B-cell activation. However,
the finding that their expression is decreased or
absent in tumours showing plasma-cell differen¬
tiation and that centrocytic lymphomas and some
centroblastic lymphomas tend to show low DQ
expression suggests that MHC class II antigens may
also be differentiation related.
Many of the histological groups of B-cell NHL
recognized by the Kiel classification system show
cytomorphological and phenotypic similarities to
normal B cells. It is generally accepted that neo¬
plastic cells reflect normal B cells frozen at various
stages of maturation. However, the phenotypic
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heterogeneity we have observed within the various
histological categories shows that direct comparison
with morphologically similar normal counterparts
cannot be made in all cases. There are a number of
possible reasons for this. Phenotypic heterogeneity
may represent multiple stages of activation/
differentiation arrest along a linear pathway which
are only transient in vivo and therefore seldom seen.
Alternatively, it may indicate maturation arrest
of morphologically similar cells which are already
committed to different non-linear differentiation
pathways. We believe that the phenotypic diversity,
especially marked in high grade NHL, in part
represents abnormal expression of differentiation
and activation antigens secondary to loss ofgenomic
regulation in neoplastic cells. As many of these acti¬
vation and differentiation antigens appear to have a
functional role in the control of B-cell differen¬
tiation and proliferation, abnormal expression may
be intimately involved in lymphomagenesis.
In conclusion, using an extended panel of MCA
against B-cell activation and differentiation antigens
we have shown marked phenotypic heterogeneity
both between and within morphological groups of
B-cell NHL. The B-cell histogenesis in many cases
could be confirmed only by using a panel of
immunoglobulin and pan B-cell markers. Pan B-cell
(CD19, 20, 22, 45R) and 'restricted' B-cell antigens
(CD5, 9, 10, OKTIO) were in general unhelpful
markers of morphological groups although CD5
(lymphocytic and centrocytic NHL) and OKTIO
(plasma cell tumours) were expressed strongly by
some groups. Activation antigens were expressed by
cases in all histological groups but 4F2 and trans¬
ferrin receptor were more often and more strongly
expressed by high grade lymphomas. They may
therefore be of prognostic significance. Other
activation antigens such as CD23 and CD25 did not
appear to be more frequently associated with high
grade tumours but CD23 may be useful in the
discrimination between centrocytic and lymphocytic
lymphoma. Studies are underway to establish
whether or not the phenotypic diversity recognized
by this extended panel of MCA is reflected by an
equivalent diversity in clinical behaviour.
Extended phenotyping by a large panel of MCA
such as we have used in this study may be of value
in elucidating biologically important characteristics
and cellular abnormalities in NHL. However, for
routine diagnostic purposes such extensive typing
ofNHL is probably not of practical use at present.
As an adjunct to routine histological examination,
we now employ a limited panel of MCA against
leucocyte antigens CD3, CD5, CD22, CD45, IgM,
kappa, and lambda. This panel allows diagnosis of
most cases of NHL. The use of additional MCA
against other leucocyte antigens (CD1, CD4, CD8,
CD 19, CD23, CD25) is undertaken only in selected
cases where the initial screen gives equivocal results.
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SUMMARY
Immunophenotyping shows heterogeneity of expression of activation and differentiation antigens in B-cell non-
Hodgkin's lymphoma (NHL). To investigate whether antigen expression correlates with clinical behaviour we have
studied the clinical presentation and follow-up of a series of 111 B-cell lymphomas previously phenotyped for a panel of
antigens including CD groups 5,9, 10,21,23,25,30,38,4F2 antigen, and transferrin receptor. CD antigens 5,10, and 23
were expressed significantly more often by low grade lymphomas whereas CD38, 4F2 antigen, and transferrin receptor
were more often expressed by high grade lymphomas. There was a significant correlation with survival and age, stage at
presentation, histological grade, and expression of4F2 antigen and transferrin receptor but not with the other antigens
studied. 4F2 antigen and transferrin receptor may identify a poor prognostic group of cases in low grade lymphoma but
we conclude that phenotyping B-cell NHL for many of the antigens expressed at various stages of B-cell differentiation
and activation does not provide clinically useful information in addition to that obtained from standard histological
classifications.
key words—Immunophenotyping, survival, B-cell non-Hodgkin's lymphoma.
INTRODUCTION
Classifications of non-Hodgkin's lymphoma
(NHL) such as the Kiel Classification1 andWorking
Formulation (WF): identify different morphologic
categories which may be separated into major
prognostic groupings. Immunophenotyping aids
categorization of NHL into T- and B-cell groups.
Extended phenotyping (i.e., detailed analysis of
the expression of a number of activation and differ¬
entiation antigens using a large panel of antibodies)
has shown phenotypic heterogeneity within mor¬
phologically similar groups.3-5 Previous studies of
antigen expression have shown a correlation with
survival in NHL although only a limited number of
markers have been used. Transferrin receptor and
4F2 expression is associated with poor survival;6,7
Addressee for correspondence: Dr D. M. Salter, Depart¬
ment of Pathology, University Medical School, Teviot Place,
Edinburgh EH8 9AG. U.K.
MT2 expression in colorectal lymphomas is
believed to be of prognostic value;8 and CD23
expression has been associated with prolonged
disease-free survival.9
To determine whether extended phenotyping
provides additional clinically useful information
we have studied the clinical presentation and
follow-up of a series of B-cell NHL which have
been phenotyped for expression of a large panel of
antigens. These antigens are expressed at different
stages of B-cell maturation, activation, and entry
into cell cycle and their expression may be expected
to be associated with clinical behaviour.
MATERIALS AND METHODS
Cases and clinical data
Clinical follow-up was obtained from case
notes of 111 cases of B-cell NHL diagnosed in
0022-3417/89/110211-10 $05.00
© 1989 by John Wiley & Sons, Ltd.
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Table I—Antibodies used for phenotyping cases ofNHL
Antibody
Mol. wt of antigen


























































































BD = Becton Dickenson; NA = not allocated; SAPU = Scottish Antibody Production Unit; Trf-R = transferrin receptor; ATCC =
American Tissue Culture Collection.
the Immunopathology Laboratory, Edinburgh
University Pathology Department during the
period July 1982 to December 1986. Biopsies were
obtained from hospitals in the Lothian Region,
Borders, and Fife. These cases were part of a
series of 145 B-cell NHL which had been previously
phenotyped,3 clinical data being unobtainable
on 34.
Histology andphenotyping
Cases were classified by the Kiel Classification
and Working Formulation following review by
D.M.S. and A.S.K. Detailed results of the immuno-
histochemical techniques used and results of immu-
nophenotyping have been reported previously.310 A
list of the antibodies used and specificity is given in
Table I. Correlation between antigen expression,
histology, and clinical behaviour was only under¬
taken for markers in the 'restricted B cell' and
'activation-associated' groups. Expression of these
antigens varies with stage of differentiation, entry
into the cell cycle, and activation of normal B
cdls 13,16,19,20,29-37 CD23 and CD25 are growth_
factor receptors.38,39 Their expression is potentially
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Table III—Antigen expression. Cases were classified as being positive if more than 30 per cent of cells showed
immunoreactivity
No. positive/No. cases tested
CD5 CD9 CD 10 CD21 CD23 CD25 CD30 CD38 Trf-R 4F2
Lymphocytic 13/13 3/13 0/13 6/6 5/6 5/13 0/2 0/13 4/13 9/13
Centrocytic 11/11 3/11 0/10 4/4 0/4 1/11 0/1 2/11 6/11 8/11
Foil Cb/Cc* 1/38 26/36 21/35 14/17 10/19 3/38 0/17 11/37 32/38 31/38
DiffCb/Cc 0/9 2/10 2/10 3/4 2/6 2/9 N.T. 0/10 7/10 10/10
Centroblastic 1/25 8/25 4/21 9/14 0/15 7/24 2/15 11/24 25/25 24/25
Immunoblastic 0/14 3/14 1/12 3/7 1/9 4/14 1/9 7/14 14/14 13/13
Kiel Classification
Low grade 25/67 32/67 23/65 25/29 17/35 10/68 0/19 12/68 46/69 55/69
High grade 1/42 13/42 5/36 14/23 1/24 12/41 3/25 19/41 42/42 40/41
WF
Low grade 14/48 27/46 21/45 18/21 15/25 7/48 0/18 10/47 33/48 37/48
Intermediate grade 12/48 15/49 6/44 18/24 2/25 11/47 2/17 14/48 41/49 45/49
High grade 0/14 3/14 1/12 3/7 1/9 4/14 1/9 7/14 14/14 13/13
"Includes three follicular centroblastic lymphomas which were grouped as high grade tumours in Kiel.
associated with uncontrolled proliferation and
aggressive clinical behaviour. The antigens in these
two groups also showed variable expression in our
initial immunophenotype analysis; strongly positive
and weakly positive/negative subsets could readily
be identified for comparison. The 'pan B cell' and
MHC class II antigens were expressed by the large
majority of lymphomas, and correlations between
positive and negative subsets could not be made.
In our previous study, antigen expression was
assessed in a semi-quantitative manner with
strongly (>70 per cent cells staining), moderately
(30-70 per cent), and weakly (5-30 per cent) positive
or negative groups being identified. For statistical
analysis in this study groups were separated
into moderate to strongly positive (> 30 per cent
positive) and weakly positive/negative subsets (< 30
per cent positive).
Statistical analysis
The non-parametric chi-square test was used.
Survival data were analysed by the algorithm of Lee
and Desu;40 multivariate regression analysis was




A total of 111 cases were studied. The histological
classification and clinical features are summarized
in Table II.
The series included 64 males and 47 females, age
range 15-88 (mean 59 years). The majority of cases
showed disseminated disease at presentation (11
stage 1, 10 stage II, 20 stage III, and 67 stage IV,
three not staged). Sixty-three of 109 cases showed
bone marrow involvement.
Cases were treated by a number of different
therapeutic regimes. These have been grouped as
simple or aggressive. Simple therapies were those
not intended to induce remission and included
radiotherapy and/or simple drug regimes (chlor¬
ambucil + prednisolone ± vincristine). Aggressive
therapy included drug regimes designed to achieve
complete remission (CHOP + bleomycin, BACOD,
MOPP, MVPP, CH1VPP M-PEEC, MCHOP +
bleomycin). Forty-six cases were given simple ther¬
apy and 69 cases aggressive therapy. Kiel high-
grade tumours were more often treated aggressively
(35 of 42) than were low grade tumours (30 of 69).
There was a strong correlation with type of therapy
and induction of complete remission (P< 0-00001),
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Table IV—Median survival of cases when separated by
clinical features and histological grade
No. Median
of survival
Clinical data cases (months) Significance
Age
< 60 years 51 50-3 P< 0-001
> 60 years 60 17-0
Stage
I 11 50-0+ P<0-012









Male 64 30-5 NS
Female 47 23-3
Bone marrow




High grade 42 14 P< <0-015
Low grade 69 31-5
Working
Formulation
High grade 14 6 P< 0-0001
Intermediate grade 49 19-7
Low grade 48 69 +
NS = Not significant; NR = no remission; PR = partial re
mission; CR = complete remission.
but none between grade of lymphoma and induc¬
tion of remission.
Immunophenotype analysis
The results of immunophenotyping are summar¬
ized in Table III. More detailed analysis of these
cases has been published previously.3 Low grade
lymphomas expressed CD5 (P< 0 0001), CD 10
(/^<0 05), and CD23 (.P<0001) significantly more
often than high grade tumours. CD38 (P< 0-01),
transferrin receptor (P< 0-0001), and 4F2 (P<0-05)
were more frequently expressed by high grade
lesions.
There was no association between antigen expres¬
sion and clinical findings including stage, bone
marrow involvement, or response to therapy.
Survival analysis
The results are summarized in Tables IV and V.
(a) Clinical data—A number of clinical par¬
ameters were associated with better survival (Table
IV). These included age less than 60 (/"< 0-001),
stage at presentation (T'<0-03), and response to
therapy (P< 0-00001). There was no association
between survival and sex or bone marrow involve¬
ment.
(b) Histology—Histological grading showed
significant correlation with survival (Table IV) for
both Kiel Classification (P < 0-015) (Fig. 1) and WF
(overall P< 0-0001; low vs. intermediate P< 0-002;
low vs. high P< 0-0001; intermediate vs. high
F<0 025)(Fig.2).
(c) Immunophenotype—Survival was correlated
with expression of individual markers for (i) all
cases; (ii) cases within histological grades, WF and
Kiel; and (iii) cases given aggressive therapy/The
results are summarized in Table V. There were
significant associations between expression of 4F2
(FcO-Ol) (Fig. 4) and transferrin receptor (Trf-
R) (Re0-015) (Fig. 3) and survival with all cases
included. Expression of 4F2 by low grade tumours
was associated with a shortened survival in Kiel
(P< 0-05), whereas Trf-R expression and survival in
low grade lymphomas reached significant levels
with WF (Re0-05) only. As almost all high grade
lymphomas expressed 4F2 and Trf-R, it was not
possible to undertake separate analysis of this
group. There was no significant association with
survival and the other antigens studied before or
after histological grading. There was no association
between survival and antigen expression in the
group ofNHLs given 'aggressive' therapy.
(d) Multivariate analysis—The association
between both 4F2 and Trf-R and survival was
independant of age, Kiel Classification, and stage
(F<0-05), but not WF. When 4F2 and Trf-R were
included together Trf-R was not independent of4F2
as a prognostic marker.
DISCUSSION
A large number of antibodies are available for
immunophenotyping lympho-proliferative lesions.
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Time(months)
Fig. I—Survival of cases of B-cell NHL grouped by Kiel Classification (P<0-015)
Time(months)
Fig. 2—Survival of cases of B-cell NHL grouped by Working Formulation (overall
P< 0-0001, HG vs. IG P< 0-025, HG vs. LG P< 0-0001, IG vs. LG P < 0-002)
Immunophenotyping is useful in clinical practice
for distinguishing between lymphoid and non-
lymphoid neoplasms, and reactive and neoplastic
lymphoid proliferation, and for determining T-
or B-cell lineage of NHL. When a large panel of
antibodies is used for phenotyping B-cell NHL,
relatively few consistent features of antigen expres¬
sion are seen; e.g., CD5 is expressed by lymphocytic
and centrocytic NHL and rarely by other B-cell
tumours.35 Phenotypic heterogeneity of histo¬
logically similar lymphomas suggests that extensive
immunophenotyping is not ofprimary benefit in the
classification of these lesions, and it is now our
practice to limit the immunophenotyping under¬
taken for diagnostic purposes.3
Previous studies have shown a correlation with
antigen expression and clinical behaviour. 4F2,
which recognizes a disulphide-linked glycoprotein
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Fig. 4—Survival of cases of B-cell NHL grouped by expression of 4F2 (FcOOl)
of unknown function expressed from early Gl on
proliferating lymphoid cells,42 and transferrin
receptor expression is associated with poor prog¬
nosis in NHL.6,742 Our investigations confirm
that strong transferrin receptor and 4F2 antigen
expression is associated with poorer prognosis43 but
we could find no association with survival and
expression of other activation and differentiation
associated antigens studied. Both 4F2 antigen and
transferrin receptor are expressed more frequently
by histologically high-grade tumours whose overall
prognosis is known to be poor. Expression of
these antigens can therefore in part be predicted
by histology, but multivariate analysis shows that
the association with survival is independent of age,
stage, and Kiel histological grade. Expression of
4F2 antigen was associated with poorer survival of
patients with low grade tumours in the Kiel Classifi¬
cation, whereas expression of Trf-R was associated
with a worse prognosis withWF low-grade tumours.
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These markers may therefore be useful for predict¬
ing clinically poor prognostic cases in low grade
lymphomas.
Other membrane associated antigens have been
shown to have prognostic significance. CD 10
myelomas behave aggressively,44 but in our series of
B-NHLs there was no significant correlation
between expression of this antigen and survival.
This is probably partly because of the large number
of low-grade follicular lymphomas we see express¬
ing CD 10 and the few cases of lymphoblastic
lymphoma (often CDlO-positive45) in our series.
CD23 expression has been associated with pro¬
longed relapse-free survival in NHL.9 This is not
unexpected as it is expressed predominantly by
low grade lesions; however, we were unable to con¬
firm an association between CD23 and survival.
Schuurman et al9 correlated the expression of a
panel ofmarkers similar to that used here (including
CD groups 9, 10, 21, 23, 25, and transferrin recep¬
tor) with relapse-free survival in cases ofNHL given
therapy intended to achieve complete remission.
This form of treatment was given to only 65 of our
cases. When these were analysed separately, we were
still unable to show an association between survival
and CD23 expression or other markers. This may in
part be a reflection of the larger proportion of low
grade lymphomas given aggressive therapy in the
study of Schuurman et al.9
While immunophenotyping ofNHL has allowed
greater understanding of the biology of this group
of neoplasms and is an invaluable research tool, the
clinical application and usefulness of many of the
antibodies used for phenotyping lymphoid cells are
in doubt. A limited panel of antibodies which aids
identification of lymphoid neoplasms and helps
ascertain lineage of these tumours is probably all
that is necessary for routine clinical use at present.
New markers need to be developed which will differ¬
entiate between good and poor prognosis cases in
histological grades, allowing the pathologist to
make more accurate predications of behaviour of
NHL. Our results suggest that 4F2 and Trf-R may
identify poor prognostic cases of histologically low-
grade NHL. Immunostaining for the proliferation
marker Ki 67 may allow similar discrimination.46
The number of different chemotherapeutic regimes
given to a series of NHLs in a retrospective study
such as this creates some problems in assessment of
associations between phenotype and clinical behav¬
iour but when potentially useful markers such as
4F2, TrF-R and Ki 67 have been identified it may
be appropriate for immunophenotype as well as
histological grade to be taken into consideration
in prospective trials of the efficacy of different
treatment modalities.
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